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Abstract
Protein secondary structure can be mimicked by incorporating structural constraints into
peptides and this can be facilitated by metal coordination. The objective of this project is to
establish a chelation system with a cancer targeting peptide sequence, where the coordination
to a metal centre results in a cyclic metallopeptide. Cyclic RGD peptides are antagonists for
αvβ3 and other integrins, which are present during tumour angiogenesis. Arg-Gly-Asp (RGD)
sequence is employed in the peptide backbone, with an un-natural amino acid (3-Pal) and a
chelating molecule (pyridyl-triazole, pyta) present on opposite ends of the peptide sequence
to form a linear peptide sequence, pyta-RGD-3-Pal-NH2. The linear peptide was reacted with
[Re(OH2)3(CO)3]+ to form a cyclic system, with the pyridyl-triazole coordinating in a
bidentate fashion. The linear peptide and resulting cyclic metallopeptide were characterized
by high resolution mass spectrometry (HRMS), Circular Dichroism (CD) spectroscopy, oneand two-dimensional 1H-NMR spectroscopy, and variable temperature (VT) NMR
spectroscopy, with purity > 90% as determined by HPLC. Computational studies on the
coordinated peptide suggested intra-molecular hydrogen bonding consistent with VT NMR
data. The linear peptide was successfully radiolabelled with Tc-99m demonstrating the
potential application as a SPECT (single photon emission computed tomography) imaging
agent for angiogenesis. This approach to adding a structural constraint, through metal-based
peptide cyclization, results in a metallopeptide where the metal is central to creating the turn
mimetic.
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Molecular imaging probe, Technetium-99m, metal-based peptide cyclization, cyclic RGD,
99m
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Chapter 1

1

Introduction
1.1

Molecular Imaging

The methods used to evaluate and visualize biological events have changed over the
years. Different imaging techniques have been introduced that provide insight into the
biological processes taking place within our body. Molecular imaging is one such
technique and can be defined as the non-invasive characterization and visualization of
biological events taking place at the cellular and molecular level.1,2 Molecular imaging
allows diseased cells and normal tissue cells to be differentiated, by targeting those
biological receptors that are overexpressed in diseased cells, while present at low
concentrations in the normal tissue cells. Several factors are taken into account when
designing a molecular imaging probe (Figure 1.1), which include: a) an appropriate
biological target, b) a targeting entity with high affinity for the chosen biological target; a
good binding target would have a dissociation constant (Kd) in nM range, and c) an
appropriate signaling source that allows the target to be detected by an external imaging
modality.1

Figure 1.1 Schematic for a molecular imaging probe.

1.2

Targeting Entity

There are a number of different kinds of targeting entities that exist, ranging from small
molecules and peptides to large biologics such as antibodies or nucleic acids. Peptides
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have increasingly gained attention as a targeting component, as they have a number of
desirable properties.2,3 The advantages of using peptides as a targeting entity include: 1)
they can be readily synthesized and the monomeric amino acid residues can be
chemically modified; 2) there are many biological receptors that display good binding
affinity towards small peptides; 3) their low molecular weight and small size allow them
to penetrate tissue and tumours, as well as to be removed from the plasma and body
relatively quickly; 4) a variety of bi-functional ligands can be attached at a peptide’s Cterminus and N-terminus; and 5) peptides display good tumour-background ratios.2-4 In
addition, small molecule drugs, and imaging molecules can be attached to peptides for a
variety of applications.5
The use of peptides as targeting entities also suffer from a number of disadvantages.
Firstly, the in vivo stability of short linear peptides is a major concern, as they readily
undergo degradation by proteases and peptidases.3, 6 Secondly, the flexible nature of
linear peptides allows them to bind to multiple receptors, which reduces their specific
binding towards the biological target.3, 6 Furthermore, the addition of an imaging source
can affect the peptide conformation and reduce the specific binding of the peptide.1
Despite these difficulties, structural constraints, such as through cyclization of the peptide
backbone, can resolve some of the difficulties seen with short linear peptides.

1.3

Solid Phase Peptide Synthesis (SPPS)

Peptides can be synthesized either in solution-phase or on a solid-phase support.
Solution-phase peptide synthesis is an efficient method; however, isolation, purification
and characterization steps are required after the addition of each amino acid, making this
a rather expensive and time consuming technique. On the other hand, solid phase peptide
synthesis (SPPS), introduced by Merrifield in 19637, is more efficient to construct large
and complex peptide sequences. With this technique, a peptide is constructed in a
stepwise manner, using an insoluble resin that fixes, the C-terminus of the peptide to the
resin. This allows the use of excess reagents, in order to ensure that the addition of each
amino acid proceeds to completion. When using this technique, the reagents and byproducts are soluble, and can therefore, be easily removed with excess washing and
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filtering without affecting the peptide which remains attached to the resin. As a result,
this eliminates the need for a purification step after each amino acid coupling.

Figure 1.2 Solid phase peptide synthesis (SPPS) employing 9-fluorenylmethoxycarbonyl
(Fmoc) strategy
In SPPS, the peptide is constructed from the C-terminus to the N-terminus, with the Cterminus attached to an insoluble resin. There are two common strategies involved with
SPPS based upon the protecting group being used, 9-fluorenylmethoxycarbonyl (Fmoc)
and tert-butoxycarbonyl (Boc). These strategies both involve orthogonal protecting
groups, which allows only the N-terminal protecting group of the peptide to be
selectively removed for the addition of the next amino acid, and the other amino acids
already coupled to the resin to remain protected. In the Fmoc strategy (Figure 1.2), the
Fmoc group is a base labile, and can be removed with piperidine in N,N-
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dimethylforamide (DMF). On the other hand, the resin, and the protecting groups on the
side chains of amino acid residues are acid labile. Once the Fmoc group is removed, the
next amino acid in the sequence is added in excess, in addition to the coupling reagent, 2(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate
(HCTU) and a base, N,N-diisopropylethylamine (DIPEA) in DMF. This cycle repeats
until the desired peptide is constructed. The peptide is cleaved off of the resin, and all of
the protecting groups are removed by vortexing the resin in an acidic solution containing
a carbocation scavenger, triisopropylsilane (TIPS). In suitable acidic conditions,
trialkylsilanes can act as hydrogen donors, and de-block the protecting groups from
additional reactions with the peptide.8 This results in a linear peptide that is purified with
reverse phase high performance liquid chromatography (RP-HPLC) and characterized by
mass spectroscopy (MS).

1.4

Structural Constraints

The exploration of peptide geometry has been of major interest in peptide chemistry.
Principal interest is the introduction of structural constraints within the peptide backbone,
in order to create effective probes for targeting biological receptors. Cyclized peptides are
to have a more rigid geometry, and therefore, when present in favorable conformations,
would result in better binding and selectivity towards the targeted receptors.5 Cyclization
of peptides results in reduced molecular conformations in solution as compared to their
linear counterparts. When these constrained peptides are used as targeting entities, the
limited number of conformations results in less competition for targeting biological
receptors. On the other hand, linear peptides undergo numerous conformations in
solution, and these conformations are present in very fast equilibrium. As a result, the
specific binding towards the targeted receptor is reduced, as different conformations
compete for interaction with the biological target.5, 9
Numerous examples have been presented, where introducing a structural constraint
results in better binding towards the targeted receptor. Kumar et al. reported cyclic
analogues of linear peptide sequence, Ac-CIYKYY, as an inhibitory agent against
activated Scr tyrosine kinase.10 Scr kinase inhibitors prevent kinases from
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phosphorylating proteins at the tyrosine site, and this inhibition slows down the
downstream signal transduction. This mechanism is used in an attempt to treat tumours.
Kumar et al. compared the linear peptide with cyclic heat-to-tail peptide analogues, and
found that the cyclic peptide (IC50 = 6.4 µM) had an inhibitory effect, 62.5-fold higher
than that of the linear peptide (IC50 = 400 µM), which is believed to be due to the
introduction of a structural constraint within the peptide backbone. They further reported
eight other cyclic derivatives of the same linear peptide sequence, using different
strategies to cyclize the peptide. Seven out of eight derivatives displayed better potency
against tyrosine kinase than the linear sequence.
Cyclization can be introduced using different strategies, such as head-to-tail cyclization,
and side-chain to side-chain cyclization. Cyclization can be presented by different bond
types, such as the formation of amide bond, disulfide bridges, metal coordination, and
several others. An example of where cyclization was introduced through amide bond
formation is cilengitide (Figure 1.3), a pentapetide cyclized from head-to-tail by the
formation of an amide bond.11 Cilengitide, c(RGDf(N-Me)V), contains a tripeptide
sequence, Arg-Gly-Asp (RGD), and is an antagonist for integrin, αvβ3. Numerous RGD
peptides have shown good binding towards integrin, αvβ3. Vitronectin competitive assays
displayed cilengitide (IC50 = 0.58 nM) to have 360-fold better binding towards αvβ3 than
the linear peptide sequence, GRGDSPK (IC50 = 0.58 µM).12 Octreotide is an example
where cyclization is introduced through disulfide bonds, formed through side chain
interactions of cysteine residues. Octreotide is a synthetic octapeptide that mimics
somatostatin, a naturally occurring hormone; it binds to the somatostatin receptor. Both
linear and cyclic octreotide displayed binding towards somatostatin receptors; however,
linear octreotide exhibits poorer binding than its cyclic analogue.13
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Figure 1.3 Structural constraints introduced through different bond types; cilengitide,
cyclization through amide bond, and octreotide, cyclization introduced by di-sulfide
bonds
Cyclization has shown improved in-vivo stability of peptides. Pakkala et al. compared the
stability of linear and cyclic peptides targeting human glandular kallikrein (KLK2) with
the sequence GAARFKVWWAAG (KLK2b).5,14 The KLK2 protein is a highly specific
prostate serine protease that is overexpressed in aggressive prostate tumors. Targeting
this protein serves a potential therapeutic to reduce the metastasis of prostate cancer. As
mentioned earlier, the in-vivo stability of short linear peptides is a major concern, as they
are readily broken down through enzymatic degradation. Here, the stability of linear and
head-to-tail cyclized KLK2b peptides in trypsin and human plasma was compared.
Trypsin behaves as a protease, and cleaves amide bond following lysine or arginine
residues. The linear KLK2b peptide completely degraded after 30 minutes in trypsin;
however, only 57% of head-to-tail cyclized peptide degraded after 4 hours, according to
HPLC analysis. In addition, the linear peptide completely degraded after 30 minutes in
human plasma, while, the cyclized peptide was still intact after 24 hours. This study
demonstrated that stability of peptides can be achieved through head-to-tail amide
cyclization.

1.5

Metal Induced Structural Constraints

Cyclization can also be introduced through metal coordination. Metals have been shown
to exhibit structural constraints when introduced within the peptide sequences. This is
commonly accomplished by developing a metal clip that will coordinate to a metal. In
literature, metal complexes have been reported to stabilize peptide sequences.15-16 A turn
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can be induced within the peptide backbone by metal coordination where the metal acts
as a central core around which a turn occurs. This is demonstrated by incorporating metal
chelators or metal chelating amino acids within the peptide backbone. A turn is an
element of secondary structure, and occurs when the peptide backbone that is in a random
coil sharply bends on itself, separated by a minimum of two amino acid residues. A turn
can be characterized based on the number of amino acids that are separating the two ends
of the cyclized peptide. Various types of turns include γ (i, i±2), β (i, i±3), α (i, i±4), α
helix (i, i±3.6); i represents the amino acid where the turn is created.17,18
Hoang et al., demonstrated helicity within the peptide backbone upon metal
coordination.19 In their study, a linear peptide, in random coil, was cyclized and a turn
was induced upon metal coordination. The natural amino acid, histidine, was used to
coordinate with the metal center. The study reported that cyclization of linear
pentapeptide, Ac-HAAAH-NH2, through Pd(en)2+ core being coordinated through
nitrogen atoms of the imidazole ring on histidine residues, present at the opposite ends of
the pentapeptide. Three linkage isomers were observed when Ac-HAAAH-NH2 was
coordinated with Pd2+, which differed in the pair of imidazole nitrogen atoms bound to
the metal. The dominant linkage isomer was a 22-membered macrocyclic metallopeptide,
which had palladium (II) bound to the peptide through two N1 atoms of the imidazole
rings (Figure 1.4). From the ROSEY NMR spectra, ROE correlations were observed for
hydrogens of the imidazole rings on His1 and His5, which suggested that they were
present in close vicinity, and that Pd2+ was bound through the imidazole nitrogen atoms
of one peptide, instead of acting as a bridging metal for two different peptides. An upfield
chemical shift in the 1H-NMR spectra of CHα is characteristic for the presence of α
helicity in the peptide backbone.20 This upfield chemical shift was observed for all CHα
atoms present in the coordinated peptide backbone, which may suggest the presence of α
helicity. The Pd2+ complexes were able to establish a reverse turn through cyclization,
and the pentapeptide was held in a stable conformational lock.
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Figure 1.4 Dominant isomer of Ac-HAAAH-NH2 coordinated with Pd2+, through N1
nitrogen atoms on both imidazole rings.19
Albrecht et al. demonstrated activation of a biological relevant linear peptide sequence
upon metal coordination.21 They introduced a metal chelator, catechol, at the opposite
ends of a tripeptide sequence, Trp-Ala-Val. This tri-peptide sequence is the backbone of
Segetalins, cyclic peptides that possess estrogen-like activity.22 Upon coordination with
molybdenum, a turn was created, giving the tri-peptide sequence a conformational lock,
and making the linear tri-peptide sequence biologically relevant. This concept can be
used to develop imaging probes that employ metal clipped peptides whose biological
activity is activated, upon coordinating with an appropriate radiometal signaling source.

1.6

Signaling Source

The signaling source is an integral component of an imaging probe. It provides energy
that is detected by imaging modalities. More commonly used imaging modalities include
computed tomography (CT), magnetic resonance imaging (MRI), positron emission
tomography (PET), single photon emission computed tomography (SPECT), and ultra
sound (US). PET and SPECT imaging employ radioactive materials as their signaling
source. PET and SPECT share similar techniques that are based on the radiotracer
principle, which states that biological events are monitored by the movement of a
radiotracer circulating within the body. However, the pathway in which radiation is
emitted and detected for PET and SPECT is fairly different.
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In both PET and SPECT imaging the radiotracer is introduced within body fluids and is
allowed to circulate until it binds to the target receptor. In both types of imaging, γ-rays
are produced and detected by gamma cameras. The gamma camera most commonly
contains sodium iodide (NaI) crystals with small amount of thallium that converts the γrays to photons. These photons are then captured by the photon multiplier (PM) tube,
which converts the photons to an electronic signal. This electronic signal is then
amplified and converted to a digital signal, which produces an image.23 PET and SPECT
isotopes are produced either by a cyclotron or a generator.
PET differs from SPECT in the way that γ-rays are emitted and subsequently detected by
gamma cameras. For example, PET isotopes, which include 18F, 68Ga, 64Cu, undergo β+
decay by emitting a positron. The positron travels a short distance before coming in
contact with an electron. This results in an annihilation event that produces two gamma
rays of 511 keV each, which travel in opposite directions (180o apart). These gamma rays
are detected by gamma cameras that are placed 360o around the body. In addition, the
half-life of PET and SPECT isotopes are different, PET radionuclides typically have halflives ranging from minutes to hours, while those of SPECT isotopes range from hours to
days.

1.7

Single Photon Emission Computed Tomography

(SPECT)
SPECT imaging employs commonly used radionuclides such as 99mTc, 111In, and 123I; all
radioisotopes decay by releasing γ-rays with different energies. The energies released
from SPECT radiotracers usually range from 100 – 300 KeV, which is strong enough to
penetrate the skin without harming other tissues. SPECT radiotracers releases a single γray that is detected by a gamma camera that circulates the whole body. SPECT
radionuclides are less expensive, low energy, and readily available. They are ideally
produced by on-site generators. SPECT radionuclides have longer half-lives ranging from
6 hours to 2.8 days, allowing for multiple syntheses, purification, and imaging of the
body.
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1.8

Technetium-99m as Signaling Source

Technetium-99m has been one of the more widely used radioactive metals to label
biomolecules. It is used as a signaling source for more than 70% of nuclear medicine
procedures.24 Technetium-99m has many desirable properties, some of which include: i)
easy availability, ii) low cost, iii) easy handling, iv), good imaging characteristics, and v)
absence of strong radiation such as α and β decay.3 99mTc is an artificial element that is
generated by a 99Mo/99mTc generator, in which 99Mo decays to 99mTc by β- decay. 99mTc is
a nuclear isomer of 99Tc present in a metastable state, which decays to 99Tc by emitting a
γ ray with an energy equal to 140 keV (Figure 1.5). The γ emission can be detected by
Single Photon Emission Computer Tomography (SPECT).

99m

Tc has a half-life of 6

hours, which is suitable for radiolabeling biomolecules, as well as acquiring images.

Figure 1.5 Decay scheme of 99Mo to 99Ru
The 99mTc metal can exist in various oxidation states; for example a +V oxidation state of
99m

Tc is observed in [99mTc=O]3+ and [99mTcN]2+, a +III oxidation state in 99mTc(III)

complexes, and a +I oxidation state in [99mTc(CO)3]+ complexes. All of these oxidation
states are the reduced form of [99mTcO4]-, where the oxidation state of 99mTc is +VII,
which is the form when eluted from the 99Mo/99mTc generator. The [99mTc(CO)3]+
complexes can be stabilized either by a tridentate chelator, a ‘2+1’ chelation system, or
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three mono-dentate ligands. A ‘2+1’ chelation system is the combination of bi-dentate
and mono-dentate ligands attached to a metal.
The +1 oxidation state of 99mTc/Re(I) octahedral complexes, results in the d6 electrons
occupying degenerate t2g orbitals (dxy, dyz, and dxz) leaving the doubly degenerate eg
orbitals (dx2-y2, dz2) empty.25 Tc/Re (I) are usually referred to as a soft metals due to the
low charge to size ratio and their preference for soft ligands, because soft-soft
interactions are considered to be stronger than soft-hard interactions.
The 99mTc(CO)3+ core is a versatile building block for a variety of biomolecules. The
carbonyl groups are known to stabilize metals with low oxidation states, such as
[Mn(CO)6]+.25 According to the molecular orbital energy diagram of a carbonyl group,
the highest occupied molecular orbital (HOMO) is a 3σ orbital and lowest unoccupied
molecular orbitals (LUMO) are antibonding π (π*). The metal-carbonyl bond involves the
HOMO (3σ) participating in a sigma bond, whereas the LUMO (π*) form π bonds with
the metal center.25 The π bonding is achieved by donation of electrons from occupied d
orbitals of the metal to doubly degenerate empty π* orbitals of the carbonyl group; this
lowers the electron density on the metal center while increasing it on the carbonyl group.
Increase in the electron density helps stabilize the carbonyl group, and in return enhances
the sigma donation to the metal center.25 The π bonding can also be referred to as πbackbonding.
The [99mTc(CO)3(OH2)3]+ complex is a convenient starting material for labeling various
biomolecules. Previously, the complex [99mTc(CO)3(OH2)3]+ was synthesized from
aqueous [99mTcO4]- in the presence of gaseous carbon monoxide, CO, and borohydride,
BH4-, as a reducing agent.26 However, the use of carbon monoxide is unsuitable for
developing radiopharmaceutical ‘isolink’ kits. Each ‘isolink’ kit contains a lyophilized
mixture of sodium carbonate, disodium boranocarbonate, sodium tartrate, and sodium
tetraborate.27 The compound K2[H3BCO2] has been reported to release CO in aqueous
solution at high temperatures.28, 29 Alberto et al. employed [H3BCO2]2-, as a reducing
agent and a potential source for CO, to form a water soluble and water stable
[99mTc(CO)3(OH2)3]+ complex.30 The reaction was performed at 90 oC for 10 minutes, in
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an appropriate buffer solution and a complexing agent (sodium tartrate), for stabilizing
the intermediate complexes. Pitchumony et al. reported microwave assisted synthesis of
[99mTc(CO)3(OH2)3]+, with reduced reaction time to 3.5 minutes at 110 oC.31 According to
the reaction conditions described above, an octahedral complex was formed with the
carbonyls trans to the aqua ligands to provide a facial orientation. The aqua ligands can
be readily replaced with incoming biomolecules.
The 99mTc chemistry is performed at a microgram scale. To explore the coordination
chemistry, rhenium (185/187Re) is used as a non-radioactive analogue. Rhenium follows
technetium in Group VII of the periodic table. Elements in the same group share similar
physical and chemical characteristics. Thus, rhenium is a suitable metal to explore
coordination chemistry for radioactive technetium.
The 99mTc/Re(CO)3+ octahedral complexes commonly exists as facial isomers; however, a
report on meridional isomer has been published.32 Due to the strong bonding between the
metal center and the carbonyl groups, the trans aqua ligands are very labile and can be
easily substituted with incoming biomolecules. Electron density from nitrogen, oxygen,
and sulfur atoms of various ligands, can be donated to the empty d orbitals of
Tc/Re(CO)3+ metal core, resulting in formation of σ bonds.

99m

1.9

Using 99mTc/Re(CO)3+ as a “2+1” Chelation

System to Induce a Turn Conformation in a Linear
Pentapeptide
The 99mTc/Re(CO)3+ core has not been reported to create and stabilize a turn
conformation within a biologically relevant peptide. However, in 2014, Simpson reported
coordination of Ac-HAAAH with the Tc/Re(CO)3+ core to create a turn conformation.33
The 99mTc/Re (I) core was coordinated through imidazole nitrogen atoms of histidine
residues present at opposite ends of the peptide. This was based on a similar approach
employed by Hoang et al.19 The facially oriented octahedral complex was cyclized
through the oxygen atom of the carboxyl group, at the C-terminus. However, instead of
having both the N1 nitrogen atoms of imidazole rings coordinated to the metal centre, as
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reported by Hoang et al.19, the peptide was coordinated through N1 and N3 nitrogen
atoms (Figure 1.6). The metallopeptide complex resulted in a 21 membered macrocycle,
and a small 7 membered ring. The peptide can be referred to as a “2+1” chelation system,
where a bidentate attack from imidazole nitrogen and carboxyl oxygen is observed at one
end, and a monodentate attack of imidazole nitrogen atom is observed on the other end.
Hydrogen bonding in the peptide backbone was reported by variable temperature (VT)
NMR and computational studies. Four hydrogen bonds were observed within the peptide
backbone. The radiolabeled peptide, with 99mTc(CO)3+, resulted in the identical dominant
isomer when coordination was demonstrated with Re(CO)3+.

Figure 1.6 Coordination of Ac-HAAAH with Re(CO)3+ through N1 and N3 nitrogen
atoms of the imidazole rings, and carboxyl oxygen at the C-terminus.33

1.10

Integrin αVβ3, as a Biological Target

Integrins are heterodimeric type I transmembrane proteins that mediate cell-cell and cellextracellular matrix (ECM) interactions. Integrin signaling regulates cell shape, cell
cycle, and cell migration.34 This is achieved by one of two ways: ‘outside-in signaling’
and ‘inside-out signaling’. For “inside-out signaling” to occur, an intracellular activator
binds to the β subunit of the integrin, resulting in a conformational change, and increasing
the binding affinity for the extracellular proteins. On the other hand, ‘outside-in
signaling’ involves a ligand binding to the integrin at the extracellular domain, resulting
in a conformational chance of the integrin structure. This subsequently promotes
intracellular signaling through signaling proteins. The “outside-in signaling’ regulates
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cell polarity, cytoskeletal structure, and cell survival, while ‘inside-out signaling’ results
in cell invasion and migration. The detached cells result in apoptosis through a series of
events.35 Preventing the binding of extracellular membrane proteins to integrins leads to
cell death and suppresses the aggression of tumour such as metastasis and angiogenesis.36
The development of antagonists that prevent the binding of ECM proteins can serve as a
potential therapeutic for tumour suppression. Besides assessing integrins as therapeutic
targets, they also make good imaging biomarkers. The targeting of integrins allows for
the evaluation anti-angiogenic and anti-therapeutic agents, and also preliminary diagnosis
of cancer.34

Figure 1.7 Simple schematic of integrin consisting of α and β subunits.
There exist 18α and 8β subunits that are non-covalently bonded to make up 24 different
pairs of integrins. α and β subunits are non-homologous in structure, but similarities
within the subunits have been observed. Integrins are composed of three major units:
large extracellular domain, single spanning transmembrane domain, and short
cytoplasmic domain.
Integrins αvβ3, α5β1 and αvβ6 are present at low concentration in normal tissues, but are
overexpressed in tumour tissues. They are known to play an important role in tumour
angiogenesis, making them an attractive target for tumour imaging.34 Some of the ECM
proteins that bind to integrins include fibronectin, fibrinogen, vitronectin, collagens,
osteopontin, etc. They all share the same cellular recognition site, a tripeptide sequence,
Arg-Gly-Asp (RGD).37 Eight of the 24 different integrins, including αvβ3, have affinity
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towards the tripeptide sequence RGD (Figure 1.8). αvβ3 is a well-studied integrin; many
antagonists, such as cilengitide, and imagining probes, have been developed to target the
receptor. It is known to be overexpressed at multiple tumour sites, including prostate,
breast, ovarian, cervical, pancreatic, melanoma, and glioblastoma tumours.

Figure 1.8 Integrins exhibiting binding towards different membrane proteins.38
Xiong et al., published the first crystal structure of Arg-Gly-Asp cyclic ligand bonded to
the extracellular domain of the integrin αvβ3 (Figure 1.9).39 Interesting characteristics
about the tri-peptide sequence were observed. The side chains of the amino acids play an
important role in the binding of the RGD ligand to the intergrin. The side chain of
arginine, which contains a guanidinium group, was held together by a bidentate salt
bridge formed with Asp218 and Asp150. The arginine interaction occurs at the α subunit of
the extracellular domain. The glycine residue occupies the space between α and β
subunits. It makes numerous important hydrophobic interactions, including hydrophobic
interactions with the carbonyl oxygen of Arg216, of the α subunit. The side chain of
aspartic acid, a carboxylate group, makes vital interactions with amino acids of the β
subunit. One of the oxygen atoms of the carboxylate group forms hydrogen bonds with
amides of Tyr122 and Asn215. The other oxygen correlates with Mn2+ at the metal-ion
dependent adhesion site (MIDAS). The side chain of aspartic acid also makes
hydrophobic interaction with the beta carbon atom of Asn215. Thus, all three amino acids
of the tri-peptide are critical for binding with integrin, αvβ3.
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Figure 1.9 Interactions between cyclic RGD peptide and integrin, αvβ3. The cyclic
peptide (yellow) making important interactions (dashed lines) with the amino acid
residues of αv (blue) and β3 (red) subunits (image adapted from Xiong et al.39)
Several linear and cyclic radiolabeled RGD peptides have been published for both
SPECT and PET imaging modalities.40,41 A 99mTc labelled linear peptide αP2
(RGDSCRGDSY) has been used to image metastatic melanoma in cancer patients.41,42
However, the lack of specificity, low binding affinity, and rapid degradation makes the
linear peptide less suitable for tumor imaging.41,43 On the other hand, cyclic RGD
peptides have shown to enhance binding affinity and improve stability. Examples of
cyclic radiotracers for PET imaging include, [18F]Galacto-RGD and
[18F]AH111585.40,44,45,46 Both cyclic RGD peptides are currently being evaluated as noninvasive imaging agents for αvβ3 in cancer patients.40 The high cost, low tumor uptake,
and lack of preparative method for repetitive radio-synthesis, will limit the use of these
peptides as imaging entities.40 A 99mTc labelled cyclic peptide, 99mTc-NC100692,
containing RGD in the backbone, has displayed good binding towards integrin αvβ3. It
has also been used to identify malignant lesions in patients with breast cancer.40,47
However, the cyclic 99mTc labeled peptide (99mTc-NC100692) has high liver uptake, and
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is rapidly excreted from the body due to the lipophilic nature of the 99mTc chelator.40
Hence, there is a continuous need to develop new techniques for the designing
radiopharmaceuticals that allows for both quick and efficient ways to introduce
radionuclides, as well as to improve in-vivo stability and targeting capability.

1.11

Thesis Scope

Figure 1.10 Project design rationale
Prior work has demonstrated that 99mTc/Re(CO)3+ is able to establish a turn within a
linear peptide sequence. This results in a conformational lock and hydrogen bonding
within the peptide backbone. We now propose cyclization of a linear peptide, with a
biological relevant sequence, RGD, through 99mTc/Re(CO)3+. To coordinate with
99m

Tc/Re(CO)3+, use of natural and un-natural amino acids as well as metal chelators

were explored. The linear and cyclized peptides were characterized with LC-MS, 1HNMR, and 2D-NMR spectroscopy. The turn was characterized with Circular Dichroism
(CD), and Variable Temperature (VT) NMR spectroscopy.
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Chapter 2

2

Employing Amino Acids to Cyclize Pentapeptides
Through “2+1” Chelation System Using 99mTc/Re(CO)3+
2.1

Introduction

Structural constraints play an important role when designing peptides that mimic native
proteins as discussed in section 1.4. Short linear peptides, less than twelve amino acids,
display poor in-vivo stability as they are rapidly broken down through enzymatic
degradation.1 Linear peptides adapt numerous molecular conformations in solution and
these conformations compete to bind to a biological target, reducing the specific binding
of the original peptide.2 Structural constraints introduced through cyclization results in
limited molecular conformations, with fewer competing for the targeted receptor,
resulting in enhanced specific binding.2
Structural constraints can be introduced by different bonds types, including cyclization
through metal coordination. Short linear peptides, less than twelve amino acids, do not
have enough flexibility and energy to induce a secondary structure within a peptide
backbone. However, a metal clip can stabilize a turn upon metal coordination.1
Palladium, iridium, rhenium, and technetium have established and stabilized a turn within
the peptide backbone.3,4,5 Histidine residues have shown to coordinate with different
metal centers in native metallo-proteins, such as copper in hemocyanin,6 zinc in
thermolysin,7 and iron in hemoglobin.8 This is normally demonstrated by coordination of
nitrogen atoms on the imidazole ring with the metal center. Metal chelating di-histidine
residues are known to be present within protein secondary structure, affecting the overall
structure of the protein, such as His-X-His in a βstrand, His-X2-His in a reverse β turn,
and His-X3-His in a α-helix.9,10 Studies have shown that incorporating metal chelating dihistidine residues enhances binding affinity, and also improves stabilization of the
protein. Kellis et al., incorporated di-histidine residues, His-X3-His, into the N-terminal α
helix of yeast cytochrome c, at the 4 and 8 position.10c Upon coordinating with Cu (II)
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iminodiacetate complex, the coordinated protein exhibited 24 times higher affinity than
the protein without the di-histidine residues. This study showed that incorporating a
suitable clip for a metal, such as histidine residues, not only improved stability of the
protein, but also enhanced its binding affinity.
Targeted technetium radiopharmaceuticals generally consist of a biological peptide
sequence for the target receptor, a pharmokinetic modifier linker, and a bi-functional
chelator for the attachment of the metal. Technetium-99m can be introduced, either
through a pendant or an integrated design. The pendant design is a classical approach
where a bi-functional chelator is attached to the peptide, through a side chain of an amino
acid or the end terminus of the peptide, Figure 2.1a. An advantage of using this design is
that it does not interfere with the targeting entity; however, because the bi-functional
chelator is covalently attached to the peptide, the metal complex is placed at a position
that can be easily cleaved through hydrolysis.11 Also, due to the bulkiness of the chelator,
it could perhaps influence the conformation of the peptide and result in decreased binding
affinity to the receptor. Therefore, structural modifications of the metal complex must be
further explored to improve the binding affinity of the peptide. Numerous examples have
been provided for

Figure 2.1 Schematic of pendant and integrated technetium-99m radiopharmaceutical
designs
An integrated design introduces the metal complex directly into the peptide backbone,
making the labelling component an integral part of the biologically active region. This
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approach ‘hides’ the metal complex within the peptide framework resulting in a more
stable, compact, and low molecular weight chelation system. Integration can be a result
of peptide cyclization or turn mimics, where the metal chelator is introduced into the turn
region of the peptide sequence (Figure 2.1b), or a chelator is formed when the peptide is
cyclized through metal coordination (Figure 2.1c). This approach eliminates the use of an
external bulky chelator resulting in low molecular weight radiopharmaceuticals.12
One of the more widely used technetium-99m core has been 99mTc(CO)3+. The
Tc/Re(CO)3+ core has been shown to stabilize through a “2+1” chelation system.13 A

99m

“2+1” chelation system is comprised of bi-dentate and mono-dentate ligands. There are
two ways to introduce “2+1” chelation system, through a pendant design or an integrated
design. Figure 2.2 represents a simplistic model of “2+1” chelation systems. Figure 2.2a
represents a pendant design, where a bi-dentate chelator is attached to the peptide through
a spacer; on the other hand, Figure 2.2b is an integrated design, where the metal complex
is incorporated into the peptide framework.

Figure 2.2 Model “2+1” chelation system
Simpson reported cyclization of the pentapeptide, Ac-HAAAH-OH, through
99m

Tc/Re(CO)3+, with a mono-dentate coordination through imidazole nitrogen at the N-

terminus, and a bi-dentate chelation through a carboxyl oxygen and imidazole nitrogen at
the C-terminus.5 We can now replace the tri-alanine sequence with a biological relevant
peptide, RGD, to target receptor, integrin αvβ3, for imaging and therapeutic purposes.
Here, efforts to cyclize RGD peptide in a “2+1” chelation fashion, with natural and unnatural amino acids, was attempted.
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Results and Discussion

2.2
2.2.1

Synthesis of [Re(CO)3(OH2)3]OTf 14

The 99mTc/Re(CO)3+ species is one of the widely used metal cores for radiochemistry,
with the aqua ligands as a convenient starting point. The aqua ligands are very labile due
to the trans effect presented by the carbonyls. The aqua ligands can be easily displaced
with the incoming ligands. Commercially available bromopentacarbonyl rhenium, 2.1,
was reacted with silver triflate, [Ag(O3SCF3)], in freshly distilled dichloromethane
(DCM), under subdued light for three hours at room temperature. The reaction mixture
was gravity filtered to remove by-product salts, silver bromide (AgBr). The product was
precipitated with addition of hexanes, and slow evaporation resulted in
pentacarbonyltriflate rhenium (I), 2.2. Compound 2.2 was reacted with water under
microwave conditions to result tris-aqua tris-carbonyl rhenium (I) species, as a 0.1 M
solution, 2.3.

Scheme 2.1 Synthetic route for [Re(OH2)3(CO)3]OTf 14, as 0.1 M solution

2.2.2

Synthesis of Ac-HRGDH-OH

The peptide was constructed from C→N terminus on a solid phase support, with the Cterminus attached to an insoluble resin. The synthesis of the linear peptide employed 9fluorenylmethyloxycarbonyl (Fmoc) chemistry. The N-terminus of each amino acid was
already protected with the Fmoc group, and the side chain of amino acid residues were
protected with acid labile groups. After the removal of the Fmoc group, an amino acid
with a base and coupling reagent in N,N-dimethylformamide (DMF) were added. The
amino acid couplings were repeated until the desired peptide was constructed. The Fmoc
group on the last amino acid, at the N-terminus, was removed and acetylated with acetic
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anhydride in DMF. The removal of protecting groups, and the cleavage of the peptide off
the resin was performed by vortexing the resin in a cleavage cocktail. The linear peptide
was precipitated with excess tert-butyl methyl ether (TBME) and centrifuged. The
centrifuged precipitates were dissolved in water and frozen over dry ice. The frozen
peptide was lyophilized to remove solvents. The peptide was purified with reverse-phase
preparative HPLC-MS (RP HPLC-MS), with a purity of >95%.

Figure 2.3 Linear Ac-HRGDH-OH, 2.4, peptide

Ac-HRGHD-OH
[M+H]+
[M+2H]2+

Calculated (m/z)
663.66
332.33

Observed (m/z)
663.34
332.25

Table 2.1 Calculated and observed m/z ratio of Ac-HRGDH-OH, 2.4, analyzed by ESILC-MS.
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2.2.3

Characterization of Ac-HRGDH-OH

Figure 2.4 1H-NMR spectrum of Ac-HRGDH-OH, 2.4, in CD3OD.
The acetylated RGD peptide was characterized with HPLC-MS and 1H-NMR
spectroscopy. Table 2.1 reports the calculated and observed m/z ratio of the peptide, and
Figure 2.4 displays the 1H-NMR spectrum in CD3-OD. After analyzing the spectra,
interesting observations were made, with glycine appearing as a prochiral molecule and
the splitting of hydrogens were observed with a pair of doublets near 3.88 ppm. The same
prochirality was observed with other methylene groups, adjacent to CHα atoms, of other
amino acids. The methylene group of aspartic acid was observed to follow an ABM spin
system, where the methylene hydrogens (Hf) were coupled with each other and at the
same time were coupled with CHα (He). The arginine methylene groups were present
around 1.5–2.0 ppm, and coupling was hard to observe. The CHα atoms were spread
from 3.75–4.75 ppm. The CH hydrogen atoms of the imidazole rings were overlapped
due to their similar chemical environment. The Ha/o was observed to have a more
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downfield chemical shift when compared with Hb/n, due to the electron withdrawing
nitrogen atoms present on both side of the proton.

Figure 2.5 1H-NMR splits of Glycine and Aspartic acid in in CD3OD.

2.2.4

“2+1” Coordination Using Natural Amino Acids as Metal
Chelators

Following the coordination procedure reported by Simpson5, Ac-H1RGDH5-OH was
reacted with [Re(CO)3(OH2)3]+. The peptide was dissolved in water, [Re(CO)3(OH2)3]+
and concentrated base, 5M NaOH, were added to the solution. Upon completion of the
reaction, the solution was lyophilized to remove the solvent. LC-MS showed the
uncoordinated peptide left at the end of the reaction. There were numerous peaks at
different retention times that corresponded to the same m/z ratio of the peptide
coordinated with Re(CO)3+, which suggested that there might be linkage isomers present.
No dominant coordinated isomeric peak was observed. The reaction was optimized to
obtain a single dominant isomeric peptide. A generic scheme used for the coordination is
displayed in Scheme 2.2, and Table 2.2 reports various conditions used to optimize the
reaction. The peaks were compared based on the area under the curve, from the LC-MS
chromatogram.
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Scheme 2.2 Synthetic approach for Ac-HRGDH-OH, 2.4, coordination with
[Re(CO)3(OH2)3]+, and proposed coordination product.

#

01

02
03
04
05
06
07
08

0.1 M
5M NaOH
[Re(CO)3(OH2)3]+
(molar
(molar Eq.)
Eq.)
1.25
1.8

1.20
1.20
1.75
1.75
1.75
1.65
0.90

1.0
1.0
1.0
0.6
1.0
7

Temp
(°C)

Time
(hours)

110
(microwave)
rt
rt
rt
rt
50
rt
rt

0.6

% coordinated vs
uncoordinated
peptide
NR

48
5
2
3
3.5
1
3

NR
96
56
18
NR
NR
97

Table 2.2 Reaction conditions used to coordinate Ac-HRGDH-OH, 2.4, with
[Re(CO)3(OH2)3]+.
Analysis of the data suggested that increasing the molar equivalent of the Re(CO)3+
species led to a lower percentage of the coordinated peptide; this could be due to side
reactions taking place when excess Re(CO)3+ was used. Unfortunately, the masses
corresponding to the undesired side products were not observed from LC-MS analysis. It
was also noted that the concentration of the base plays an important role in peptide
coordination. The reaction proceeded to completion at a higher pH (~9-10); this could be
due to high pH allowing for full deprotonation of the carboxyl group at the C-terminus
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and aspartic acid. Compound 8, showed near complete conversion of the linear peptide to
the coordinated peptide, with the peptide coordinated in the tridentate fashion.
After optimizing the reaction, a reproducible method was obtained that produced a
dominant isomer. A sub-stoichiometric [Re(CO)3(OH2)3]+ and a basic pH solution, led to
a higher percentage of the coordinate peptide, and a single dominant isomer (major peak
of the spectrum) was observed. The coordinated peptide was purified by RP HPLC-MS,
but unfortunately the major peak was not isolated as it was present in close proximity
with other isomeric peaks. An appropriate preparative gradient was not found that was
capable of separating the peaks.

Figure 2.6 Coordination of di-aspartic acid to Re(CO)3+ 15
The side chain functional groups of arginine (guanidine) and aspartic acid (carboxylate,
Figure 2.6) have potential to be involved in coordination with the Tc/Re (I).15 Protecting
the side chain functional groups of amino acids could perhaps have led to a lower number
of coordination sites and linkage isomers. The protected peptide (Ac-His(trt)-Arg(pbf)Gly-Asp(OtBu)-His(trt)-OH, 2.5) was synthesized on a 2-chlorotrityl resin and cleaved
off the resin with acetic acid, trifluroethanol and DCM. This resulted in a linear peptide
with all the protecting groups present on the amino acid side chains. The peptide was
purified with preparative RP HPLC-MS, with a purity of >95%. Coordination to
[Re(CO)3(OH2)3]+ was demonstrated by dissolving the peptide in methanol, adding
[Re(CO)3(OH2)3]+ and 5M NaOH to the solution. The reaction was stirred at 50 °C for 3
hours. Upon completion of the reaction, the solvent was removed under reduced pressure.
The LC-MS spectra showed traces of the peptide coordinated to Re(CO)3+, but the
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quantity was very low and did not permit further analysis. The peptide might have been
too bulky and sterically hindered to coordinate with Re(CO)3+.

2.2.5

“2+1” Mixed Coordination with an External Mono-Dentate
Chelator

From literature, the heterocycles imidazole and pyridine are known ligands that bind to
different metals, including 99mTc/Re.16 Using peptides to result in a “2+1” chelation
system gave numerous isomers, therefore, attempts to use a mixed chelation system was
proposed. The concept was to employ the imidazole rings on the terminal histidine
residues to act as mono-dentate ligands, replacing two of three aqua ligands. This results
in the peptide acting as a bidentate chelator in whole, creating a turn within the peptide
backbone. Replacement of the remaining aqua molecule was explored with different
metal ligands. This still follows the integrated design. The “2+1” mixed chelation system
was recently proposed by Pitchumony et al.13 and Connell et al.17
To reduce the number of coordination sites on the peptide, the free carboxyl group at the
C-terminus was replaced with a terminal amide. The linear peptide, Ac-HRGDH-NH2
(2.6), was first reacted with [Re(CO)3(OH2)3]OTf, and after the first step was completed,
pyridine was added and the reaction mixture was heated. The reaction was monitored
with LC-MS. Table 2.3 reports the reaction with different molar equivalent of pyridine.

Scheme 2.3 Synthetic approach towards mixed “2+1” Re(CO)3+ complexes, and a
proposed coordination product.
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#

Pyridine
(molar Eq.)

% of “2+1” mixed
coordination system

1
2
3
4
5

1.3
10
100
1000
1300

90.5
90.9
99.5
99.8
No evidence of the peptide
acting as a tridentate chelator

Table 2.3 Increasing molar equivalent of pyridine led to higher % of [Re(CO)3(AcHRGDH-NH2)(py)]+.
Analysis of the reaction prior to the addition of the pyridine suggested that the peptide
was coordinated to Re (I) core in a tridentate fashion. The specific connectivity of the
peptide with the Re (I) metal center is uncertain; this could be due to functional groups of
amino acids, such as aspartic acid or arginine coordinating to Re(CO)3+. When the second
step of the reaction proceeded using a low molar equivalent of pyridine, the majority of
the product was still the peptide coordinated to the Re (I) center in a tridentate fashion.
Attempting the reaction with excess pyridine led to a mixed “2+1” coordination of the
peptide with the pyridine attached to the Re (I) center. The resulting complex was
positively charged. Two isomeric peaks were observed by analytical HPLC-MS, which
can be separated with preparative RP HPLC-MS. However, the “2+1” mixed
coordination system resulted in very poor yields. Upon addition of an external ligand, the
pyridine displaced previously formed coordination bonds. This resulted in three pyridine
molecules attached to the Re (I) center to form [Re(CO)3(py)3]+, with each pyridine
acting as a mono-dentate ligand. Other metal coordinating ligands, such as Nmethylimidazole, imidazole and methylbenzylimidazole were also explored; however,
none of them displayed good yields. The “2+1” mixed coordination system was
abandoned due to poor yields.

2.2.6

“2+1” Coordination with Un-natural Amino Acids as Metal
Chelators

Using histidine as a metal chelator resulted in numerous coordinated isomers. This could
have been due to histidine residues having multiple coordinating sites. Histidine, when
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employed as a bi-dentate chelator, was placed at the C-terminal and N-terminal of the
peptide. Histidine, when coordinated, formed a 7 or 8 membered ring, when used as a bidentate chelator at the C-terminus; and 6 or 7 membered ring when placed at the Nterminus. The five membered chelate rings are generally very stable, as they don’t
present extra ring strain.18 The larger chelate rings, such as seven membered ring, are
generally less stable due to the distortions of the bond angles and unfavorable steric
interactions.18 A better chelator with less coordinating sites, and forming favorable sizes,
was explored.

Figure 2.7 Bi-dentate coordination at the C-terminal or N-terminal when using histidine
residue as a metal chelator
Pyridine and pyridine analogues are metal ligands that can coordinates with various metal
centers in a mono-dentate fashion. Un-natural amino acids (Figure 2.8) containing
pyridine as their side chain, such as 3-pyridylalanine, 2-pyridylalanine, and 4pyridylalanine, were explored. 2-pyridylalanine (2-Pal) and 3-pyridylalanine (3-Pal)
forms 6 and 7 membered rings, respectively, when used as bi-dentate chelators at the Nterminus. 2-/3-Pal amino acid residues were incorporated at the N-terminus of a peptide,
while 3-/4-Pal amino acid residues were incorporated at the C-terminus as a monodentate ligand. Different combinations of pyridylalanine amino acid residues were used at
the two end terminals, to derive a variety of linear peptide sequences with RGD in the
backbone, for example 2-Pal-RGD-4-Pal-NH2. Each linear peptide was manually
synthesized with Fmoc chemistry, and characterized with LC-MS. Each peptide was
purified with RP HPLC-MS, with a purity > 95%.
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Figure 2.8 Bidentate coordination at the N-terminus of pentapeptides using un-natural
amino acids as metal chelators

Compound

Peptide sequence
Ac-3-Pal-RGD-3-Pal-OH
Ac-3-Pal-RGD-3-Pal-NH2

Calculated
[M+H]+
685.71
684.73

Observed
[M+H]+
685.29
684.25

2.7
2.8
2.9
2.10
2.11

H-3-Pal-RGD-3-Pal-OH
H-2-Pal-RGD-4-Pal-NH2
H-2-Pal-RGD-3-Pal-NH2

685.71
642.69
642.69

686.22
643.11
643.16

Table 2.4 Synthesized peptide sequences for coordination with Re(CO)3+, employing
pyridylalanine amino acid residues at end termini.
The linear peptides were reacted with Re(CO)3+ under various conditions, such as acidic
pH, basic pH, neutral pH, microwave heating, and traditional heating. LC-MS analysis
displayed multiple isomers forming when the peptide was coordinated with Re(CO)3+.
Table 2.4 reports linear peptides that were synthesized and reacted with Re(CO)3+. Fewer
isomers were observed compared to when histidine residues were used as metal chelators.
However, dominant isomers were present in close proximity with other isomers, and
isolating a single isomer presented a challenge. Of all peptides, Ac-3-Pal-RGD-3-Pal-
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OH, 2.8, displayed good separations between the isomers, and a single isomer was
isolated.

Scheme 2.4 Synthetic approach for Ac-3-Pal-RGD-3-Pal-OH, 2.8, coordination with
[Re(CO)3(OH2)3]+, and proposed product.
The bi-dentate coordination could occur at the C-terminus through the free carboxyl and
through the nitrogen atom of the pyridine on 3-Pal, forming an eight membered ring. A
single isomer was isolated, at the retention time of 4.5 minutes; however, the stability of
the isolated isomer was an issue. The stability of the coordinated isomer was monitored
by leaving the isomer in water/acetonitrile solution over couple days at room
temperature, and then characterizing by LC-MS. Figure 2.9 shows the MS traces of
[Re(CO)3(3Pal-RGD-3Pal-OH)]OTf as a crude mixture and of an isolated isomer. In
solution, the isomer was interconverted into different isomeric form. The difference in the
retention time of the peaks, could be a result of different injection time.

37

Figure 2.9 MS traces of [Re(CO)3(3Pal-RGD-3Pal-OH)]OTf as crude mixture and
isolated isomer

2.3

Conclusion

Cyclization of a pentapeptide containing a biological relevant sequence, RGD, in the
peptide backbone was attempted. Natural, histidine, and un-natural amino acids, 2/3/4pyridylalanine, were employed to accomplish the coordination with Re(CO)3+. Most
peptides resulted in multiple isomers that were formed upon metal coordination and the
isomers were present in close proximity with other isomers. Isolating a single isomer for
further analysis presented a challenge. Ac-3-Pal-RGD-3-Pal-OH demonstrated good
separation between its isomers, and a single isomer was isolated. However, stability of
the isolated isomer was a major issue as it interconverted to different isomer over days at
room temperature in a mixture of acetonitrile and water. A strong chelation system that
results in limited linkage isomers, with good chromatographic separation is desired.

2.4

Experimental

All the reagents and solvents were purchased from Sigma Aldrich, Chem-Impex, Nova
BioChem, and the Fmoc protected amino acids were purchased from Peptide
International and Apptec, and were used without further purification. Analytical HPLC-
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MS was performed using a Waters Atlantis T3 C18 column 4.6 x 150 mm, 5 µm.
Preparative RP HPLC-MS was performed using a Waters Atlantis T3 Prep C18 OBD
column 19 x 150 mm, 5 µm. A gradient system was used consisting of: CH3CN + 0.1%
v/v trifluoroacetic acid, TFA, (solvent A) and H2O + 0.1% v/v TFA (solvent B), and the
absorbance was detected using a Waters 2998 Photodiode Array Detector. Electrospray
Ionization (ESI) mass spectrum was obtained using a Micromass Quatro Micro LCT
mass spectrometer.

2.4.1

Small Molecule Synthesis

Tris-aqua tris-carbonylrhenium (I) triflate, 2.3
Commercially available bromopentacarbonyl rhenium (I) (1.22 g, 3.0 mmol) was added
to a dry round bottom flask, and dissolved in freshly distilled dichloromethane (40 ml).
Silver triflate (0.98g, 3.8 mmol) was weighed out under subdued light, and added to the
flask with increased nitrogen flow. The flask was covered with aluminum foil, and stirred
at room temperature for three hours. After three hours, the side product, silver bromide,
was removed with vacuum filtration. The resulting solution was evaporated with reduced
pressure to half volume (20 ml). Hexanes (20 ml) were degased in a 50 ml round bottom
flask, by bubbling nitrogen through for 30 minutes. Dry hexanes were added, and the
solvent was slowly removed with reduced pressure, resulting in 1.3 g (91%) of white
powder. A suspension of pentacarbonylrhenium (I) triflate (0.5 g) in water (10.41 ml)
was prepared for microwave reaction. The reaction was performed at 120 oC for 30
minutes, which resulted in 0.1 M [Re(CO)3(OH2)3]+ solution. The resulting solution was
characterized by LC-MS.

2.4.2

Peptide Synthesis

Peptides were synthesized from C⟶N terminus using standard Fmoc Solid Phase
Synthesis (Fmoc-SPPS) approach. Synthesis was carried out manually at room
temperature. Fmoc protected Rink amide (0.54 mmol/g), Wang (0.48 mmol/g loading),
and 2-chlorotrityl (0.34 mmol/g loading) resins were used as solid support. Wang and 2chlorotrityl resin were pre-loaded with Histidine with trityl as a protecting group. The
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resin was swollen in dichloromethane (DCM) for 15 minutes. The Fmoc group was
removed using 20% piperidine in N,N-dimethylformamide (DMF) over two cycles (5 and
15 minutes). Coupling reactions were carried out with 3 eq. Fmoc protected amino acid, 3
eq. HCTU (2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3tetramethylaminiumhexafluorophosphate) and 6 eq. of DIPEA (N,Ndiisopropylethylamine). Each cycle was vortexed for 60-90 minutes. The resin was
washed with excess DMF and DCM after each coupling and de-protection cycles. The N
terminus of the peptide was acetylated after removing the Fmoc protection from the last
amino acid, using 15% acetic anhydride in DMF for 20 minutes, repeated twice. The
acetylated peptide was cleaved off the resin with 95% (v/v) trifluroacetic acid (TFA),
2.5% (v/v) triisopropylsilane (TIPS) and 2.5% (v/v) H2O. The cleavage was performed
for 4 hours. The cleaved peptide was precipitated with tert-butyl methyl ether (TBME),
and centrifuged at 4000 rpm for 10 minutes. After decanting, the peptide was frozen and
lyophilized to remove any remaining solvents. The peptide was purified with reverse
phase preparative LC-MS, and the purity was checked by analytical HPLC. Each of the
following peptides synthesized resulted in purity > 95%.
Ac-HRGDH-OH, 2.4
The peptide was synthesized manually on a Wang resin employing the same
methodology that is explained above. ESI-LC-MS m/z calcd. for C26H38N12O9 [M+H]+
663.66 and [M+2H]2+ 332.33, found [M+H]+ 663.34 and [M+2H]2+ 332.25. 1H-NMR
Spectrum (400 MHz, CD3-OD, δ): 8.79 (1H, d, imidazole, 4JH-H = 1.6 Hz), 8.78 (1H, d,
imidazole, 4JH-H = 1.6 Hz), 7.36 (1H, s, imidazole), 7.36 (1H, s, imidazole), 4.70 (1H, dd,
CH of His, 3JH-H = 6 Hz, 3JH-H = 4.4 Hz), 4.68 (1H, dd, CH of His, 3JH-H = 6.4 Hz, 3JH-H =
4.4 Hz), 4.62 (1H, t, CH of Arg, 3JH-H = 6.4 Hz), 4.32 (1H, dd, CH of Asp, 3JH-H = 5.6
Hz), 3.88 (1H, pair of doublets, CH2 of Gly, 2JH-H = 16.8 Hz, 2JH-H = 16.4 Hz), 3.80 (1H,
d, CH2 of Gly), 3.37 (1H, dd, CH2 of His, 2JH-H = 11.2 Hz, 3JH-H = 4.8 Hz), 3.28 (1H, dd,
CH2 of His, 2JH-H = 10 Hz, 3JH-H = 6 Hz), 3.20 (1H, dd, CH2 of His, 2JH-H = 7.4 Hz, 3JH-H =
4.4 Hz), 3.12 (1H, dd, CH2 of His, 2JH-H = 10 Hz, 3JH-H = 7.2 Hz), 3.22 – 3.09 (2H, m, CH2
of Arg), 2.81 (2H, m, CH2 of Asp, 2JH-H = 17.2, 3JH-H = 7.96 Hz), 1.97 (3H, s,
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CH3C(O)NH), 1.90 (1H, m, CH2 of Arg), 1.77 (1H, m, CH2 of Arg), 1.67 (2H, m, CH2 of
Arg).
Ac-His(trt)-Arg(pbf)-Gly-Asp(OtBu)-His(trt)-OH, 2.5
The peptide was synthesized manually on a 2-chlorotrityl resin using standard SPPS. The
peptide was cleaved off the resin using cleavage cocktail with (v/v) equivalence (1eq)
acetic acid: (2eq) trifluoroethanol: (7eq) DCM solution. The peptide was stirred in the
cleavage cocktail for 2.5 hours, and the solvent was removed with reduced pressure. The
peptide was purified with preparative RP LC-MS, and the purity was checked with
analytical HPLC-MS. ESI-LC-MS m/z calcd. for C81H90N12O12S [M+H]+ 1456.7 and
[M+2H]2+ 728.9, found [M+H]+ 1456.6 and [M+2H]2+ 728.6
Ac-HRGDH-NH2, 2.6
The peptide was synthesized manually on a Rink Amide resin using general SPPS. ESILC-MS m/z calcd. for C26H39N13O8 [M+H]+ 662.7 and [M+2H]2+ 331.8, found [M+H]+
662.3 and [M+2H]2+ 331.7
Ac-3-Pal-RGD-3-Pal-OH, 2.7
The peptide was manually synthesized on 2-chlorotrityl resin using general SPPS.
Removal of all the protecting groups and cleavage of the peptide of the resin was
achieved with 95% (v/v) trifluroacetic acid (TFA), 2.5% (v/v) triisopropylsilane (TIPS)
and 2.5% (v/v) H2O. The cleavage was performed for 4 hours at room temperature. ESILC-MS m/z calcd. for C30H40N10O9 [M+H]+ 685.71 and [M+2H]2+ 343.36, found [M+H]+
685.29 and [M+2H]2+ 343.22.
Ac-3-Pal-RGD-3-Pal-NH2, 2.8
The peptide was manually synthesized on a Rink Amide resin using general SPPS. ESILC-MS m/z calcd. for C30H41N11O8 [M+H]+ 684.73 and [M+2H]2+ 342.87, found [M+H]+
684.25 and [M+2H]2+ 342.72.
H-3-Pal-RGD-3-Pal-OH, 2.9
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The peptide was synthesized manually on a Rink Amide resin using general SPPS. The
N-terminal amino acid was not acetylated. ESI-LC-MS m/z calcd. for C28H38N10O8
[M+H]+ 685.71, found [M+H]+ 686.22.
H-2-Pal-RGD-4-Pal-NH2, 2.10
The peptide was synthesized manually on a Rink Amide resin using general SPPS. The
N-terminal amino acid was not acetylated. ESI-LC-MS m/z calcd. for C28H39N11O7
[M+H]+ 642.69, found [M+H]+ 643.11.
H-2-Pal-RGD-3-Pal-NH2, 2.11
The peptide was synthesized manually on a Rink Amide resin using general SPPS. The
N-terminal amino acid was not acetylated. ESI-LC-MS m/z calcd. for C28H39N11O7
[M+H]+ 642.69, found [M+H]+ 643.16.

2.4.3

Re(CO)3+ Coordination

Coordination of Ac-HRGDH-OH with [Re(CO)3(OH2)3] +
The acetylated peptide, 2.4, (11.5 mg, 0.011 mmol, 1.0 eq) was dissolved in water (5 ml)
and methanol (0.5 ml); Re[(CO)3(OH2)3]+ (103.33 µL, 0.010 mmol, 0.9 eq) and 5 M
NaOH (80.4 µL, 0.080 mmol, 7 eq) were added to the solution. The reaction was
performed for 3 hours, and monitored by UPLC-MS every half hour. The solution was
frozen and lyophilized to remove solvents. A RP SNAP C-18 cartridge was used to purify
the coordinated peptide on an automated Isolera flash column. Water and methanol were
used as solvents. Gradient included (water in methanol): 0-15% (150 ml), 15-15% (45
ml), 15-50% (150ml), 50-50% (45ml), 50-95% (105 ml), and 95-95% (45ml). ESI-LCMS m/z calcd. for C29H37N12O12Re [M+H]+ 932.9 and [M+2H]2+ 466.9, found [M+H]+
933.3 and [M+2H]2+ 467.1
Synthesis of Re[(CO)3(Ac-HRGDH-NH2)(py)] +
The acetylated peptide, 2.6, (10 mg, 9.0 µmol, 1.0 eq) was dissolved in methanol (5 ml),
0.1 M [Re(CO)3(OH2)3]+ (90 µL, 8.1 µmol, 0.9 eq) and 5 M NaOH (50 µL, 4.5 x 10-2
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mmol, 5.0 eq) were added to the solution. The reaction was performed for 3 hours, and
then pyridine (100 eq, 80.5 uL) was added to the reaction mixture. The reaction mixture
was further stirred for an hour at 45 °C. An excess TBME was added to the reaction
mixture, and the resulting solution was centrifuged for 10 minutes at 3000 rpm. The
precipitates were frozen and lyophilized for further analysis. ESI-LC-MS m/z calcd. for
C34H44N12O11Re+ [M]+ 1011.0 and [M+H]2+ 506.5, found [M+H]+ 1011.7 and [M+2H]2+
506.1
Synthesis of [Re(CO)3(Ac-3-Pal-RGD-3-Pal-NH2)]OTf
The acetylated peptide, 2.8, (30 mg, 44 µmol, 1 eq) was dissolved in a mixture of
methanol (2 mL) and water (1 mL). The pH of the solution was adjusted to 7 by adding
phosphate buffer saline (3 mL). The [Re(CO)3(OH2)3]OTf (434 µL, 43.4 µmol, 0.99 eq)
solution was then added to the reaction mixture, and stirred at room temperature for 2.5
hours. The reaction mixture was lyophilized and purified by preparative HPLC-MS. ESILC-MS m/z calcd. for C33H41N10O12Re [M+H]+ 955.24 and [M+2H]2+ 478.12, found
[M+H]+ 955.40 and [M+2H]2+ 478.09.

2.5
1.
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Chapter 3

3

A Turn Induced by 99mTc/Re (I) Tricarbonyl Coordination
to Form Cyclic Metallopeptides
3.1

Introduction

Peptides over the past decade have gained a great interest as targeting entities for drug
delivery and discovery agent. There are wide range of biological receptors that have
affinity towards peptides, for example integrins, growth hormone secretagogue receptor
1a, and gastrin releasing peptide receptor.1,2,3 Peptides as a class of biomolecules have
many desirable properties such as rapid body clearance, high binding affinity towards
targeted receptors, easy chemical synthesis.4,5 With all these advantages using peptides as
targeting entities for imaging molecules present, the in-vivo stability of short linear
peptides still remains a major concern, as they are readily broken down through
enzymatic degradation. Many techniques have been presented to improve the stability
and binding affinity of linear peptides; introducing structural constraints within the
peptide backbone is one such technique. Peptide macro-cyclization can be introduced
through various bond types such as covalent bonds, for example disulfide bridge and
amide linkage, and also hydrocarbon stapling. Metal based cyclization provides another
approach to introduce structural constraints within peptides. Many studies have been
presented that investigate the effect of metals on stabilizing peptide turns.6,7,8
In 2014, Ma et al. reported cyclization of a linear peptide, HAAAH, through Ir (III)
complexation.9 They further evaluated this easy-to-use cyclization by replacing the trialanine sequence with a biological relevant peptide, RGD. The cyclized RGD peptide
showed better protein-protein interactions than the linear peptide. Peptide cyclization
through rhenium and technetium, instantly allows the peptide to have potential use as an
imaging agent and radio-therapeutic. In 2014, Simpson reported cyclization of the
HAAAH through rhenium and technetium centres.10 We now report on peptide
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cyclization through rhenium and technetium coordination, with a biological applicable
peptide in the backbone.

3.2
3.2.1

Results and Discussion
Strategy

The addition of structural constraints is an approach to peptide modification that has been
shown to improve in-vivo stability and receptor affinity for biologically relevant peptides.
Cyclizing a peptide backbone through 99mTc/Re(CO)3+ coordination is a unique approach
that has not been thoroughly investigated. Employing 99mTc/Re(CO)3+ as a structural
constraint allows the peptide to be potentially used as an imaging probe. 99mTc/Re(CO)3+
as octahedral complexes, occupies lower energy orbitals, which can be stabilized with
aromatic amines, such as pyridine, triazole, and imidazole.11 Pyridyl-triazole have been
shown to coordinate with Re(CO)3+ in a bi-dentate fashion.12,13 Derivative of pyridyltriazole can be incorporated within the peptide backbone for metal coordination. Pyridyltriazole, pyta, is established at the C-terminus of the peptide sequence; and 3pyridylalanine (3-Pal), containing pyridine as a side chain, is inserted at the N-terminus
of the peptide. We demonstrate the cyclization of a biologically relevant peptide
sequence, comprised of the tripeptide RGD in the backbone, upon metal coordination
with full in-depth characterization and analysis. To further investigate the structural
geometry within the RGD backbone, D-amino acids were explored.

Figure 3.1 Structures of pyridyl-triazole (pyta) and 3-pyridylalanine (3-Pal)
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3.2.2

Peptide Synthesis

The peptide, pyta-RGD-3Pal-NH2, was synthesized by Fmoc solid-phase peptide
chemistry, using rink amide resin as the solid support. Each amino acid couplings was
performed for an hour at room temperature, in the presence of a coupling reagent (2 -(6chloro-1H-benzotriazole-1-yl)-1,1,3,3 -tetramethylaminium hexafluorophosphate, HCTU;
2 - (7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate,
HATU) and a base (DIPEA) in DMF. Pyridyl-triazole (pyta) was synthesized according
to a previously published procedure, scheme 3.1.14,15 The t-butyl group was thermally
cleaved under microwave conditions.16 Pyridyl-triazole, pyta, was vortexed for an hour at
room temperature in the coupling solution, consisting of TSTU (N,N,N′,N′-tetramethyl-O(N-succinimidyl)uronium tetrafluoroborate) and DIPEA in DMF, to prepare the preactivated ester. Removal of all the protecting groups and cleavage off the resin was
achieved by vortexing the resin in a cleavage cocktail (95% (v/v) trifluroacetic acid
(TFA), 2.5% (v/v) triisopropylsilane (TIPS) and 2.5% (v/v) H2O). The peptide was
precipitated, centrifuged, and lyophilized to remove residual solvents. The linear peptide
was then purified by RP-HPLC-MS, with a purity > 95%.

Scheme 3.1 Synthetic route for pyridyl-triazole (pyta).
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Scheme 3.2 Synthesis of pyta-RGD-3Pal-NH2, 3.4, employing SPPS

3.2.3

1

H-NMR Analysis of pyta-RGD-3-Pal-NH2

The linear peptide was characterized by LC-MS, 1H-NMR and two dimensional gCOSY
NMR spectroscopy. The NMR experiments were performed in deuterated dimethyl
sulfoxide (DMSO-d6) at 25 oC. Bundi et al. reported proton chemical shifts of twenty
amino acids in the peptide sequence, TFA-Gly-Gly-X-Ala-OCH3; where X is one of the
natural twenty amino acids.17 The linear peptide adopts a random conformation in
solution, and proton chemical shifts reported by Bundi et al. were used as a reference for
identifying chemical shifts of amino acids in the linear peptide sequence, pyta-RGD3Pal-NH2. Circular Dichroism (CD) spectroscopy confirmed that the linear peptide
adopted a random coil conformation. It is important to note that the proton chemical shift
of an amino acid is influenced by neighboring amino acids, as demonstrated by Wishart
et al.18 They compared two sets of peptide sequences, Gly-Gly-X-Ala-Gly-Gly and GlyGly-X-Pro-Gly-Gly, and found that substituting a proline for an alanine had a significant
effect on the chemical shift of Hα, for the X amino acid. Table 3.1 reports proton
chemical shifts of αCH, βCH2, NH, and others protons for amino acids present in the
backbone of pyta-RGD-3Pal-NH2, 3.4.
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Residue
3-Pyridylalanine
Aspartic acid
Glycine
Arginine

NH
7.55
8.71
8.86
8.73

Hα
4.36
4.25
3.98, 3.48
4.39

Hβ
3.12, 2.90
2.54, 2.23
2.02, 1.63

Others

γCH2 1.62, 1.54; δCH2 3.17, 2.99

Table 3.1 Amino acids’ proton shifts (ppm) of the linear peptide, pyta-RGD-3-Pal-NH2,
3.4

3.2.4

Re(CO)3+ Coordination

The synthesis of rhenium tris-carbonyl complexes was demonstrated by reacting the
linear peptide, pyta-RGD-3Pal, with two different rhenium (I) centres, Re(CO)5Br and
[Re(CO)3(OH2)3]OTf. Tris-aqua tris-carbonyl rhenium (I) triflate,
[Re(CO)3(OH2)3]OTf,19 was synthesized according to the previously described procedure
by Schmidt et al., from commercially available bromopentacarbonyl rhenium (I),
Re(CO)5Br. [Re(CO)3(OH2)3]+ is water soluble and serves as an analogue for
[99mTc(CO)3(OH2)3]+. Rhenium coordination was established under microwave
conditions, in water. Upon coordination, the crude mixture was analyzed by LC-MS, and
purified by preparative reverse phase HPLC MS. Both rhenium (I) cores produced similar
dominant isomeric traces, according to LC-MS. A single isomer was isolated, with a
purity of ~ 90%.
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Scheme 3.3 Re(CO)3+ coordination of pyta-RGD-3Pal-NH2, 3.4. Reactions and
conditions i) 0.95 eq 0.1 M [Re(CO)3(OH2)3]OTf, 105 oC, 1 hour, water; ii) 0.95 eq
[Re(CO)5]Br 105 oC, 1 hour, water.

3.2.5

Characterization of [Re(CO)3(pyta-RGD-3-Pal-NH2)]OTf

The linear peptide and rhenium coordinated peptide were analyzed by electrospray
ionization mass spectrometry, and both the peptides were present with a di-cationic
charges. Upon coordination with the metal, an isotopic rhenium signature was observed
for 185Re and 187Re.
Residue
3-Pyridylalanine
Aspartic acid
Glycine
Arginine

NH
7.37
7.16
8.41
9.31

Hα
4.42
4.30
3.81, 3.52
4.18

Hβ
3.12, 2.47
1.63, 1.62
1.78, 1.69

Others

γCH2 1.53; δCH2 3.18

Table 3.2 Amino acids’ proton chemical shifts (ppm) of the coordinated peptide, pytaRGD-3Pal-NH2-Re(CO)3+.
The coordinated peptide was characterized by 1H-NMR, and two dimensional 1H-1H
NMR spectroscopy. The proton chemical shifts of the coordinated peptide are reported in
Table 3.2. The NMR experiments were performed in DMSO-d6 at 25 oC. A number of
interesting observations were made when comparing the proton chemical shifts of linear
and coordinated peptides. The chemical shifts of the NH for all the amino acids, except
arginine, resulted in an up-field shift upon metal coordination. The significant downfield
NH shift of arginine could be a result of Re(CO)3+ being present in close proximity,
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thereby influencing the amide bond. Also, the CHα chemical shifts of 3-pyridylalanine
and aspartic acid resulted in a downfield shift; whereas CH arginine had an up-field
chemical shift.

Figure 3.2 Partial 1H-NMR spectra (600 MHz, DMSO-d6, 25 oC) of the linear peptide,
3.4 and coordinated peptide, 3.5
To identify the coordination sphere, 1H-NMR spectra of the linear peptide and the
rhenium complex were compared.1H-1H gCOSY was used to identify proton chemical
shifts of linear and coordinated peptides. Upon coordination with Re(CO)3+, downfield
shifts of the aromatic protons for pyridyltriazole and pyridine were observed. This
downfield chemical shift was most evident for the trizaole proton that shifted from 8.51
ppm in the linear peptide to 9.00 ppm in the Re(CO)3+ coordinated peptide, Figure 3.2.
The downfield chemical shifts of these aromatic protons provides evidence that
coordination with Re(CO)3+ involves pyridyl-triazole and pyridine, and that the
coordination sphere correlates with the proposed structure. Also, the methylene
hydrogens (labelled as 10) are significantly separated upon Re(CO)3+ coordination; this
further supports the hypothesis that pyridyl-triazole, pyta, is bidentate coordinated to
Re(CO)3+.
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Figure 3.3 Partial 1H-NMR spectra (600 MHz, DMSO-d6) of the linear peptide (top, 3.4)
and coordinated peptide, [Re(CO)3(pyta-RGD-3Pal-NH2)]OTf (bottom, 3.5).

3.2.6

Circular Dichroism (CD) Spectroscopy

Circular Dichroism (CD) spectroscopy is a widely used technique to determine the
secondary structure of proteins and peptides.20 CD spectroscopy can be used to
demonstrate a difference in peptide conformation, for example between a random coil
(linear) and an ordered structure (cyclic).21,22 Analysis of the CD spectrum of the linear
peptide, 3.4, showed one strong minimum at 200 nm. This strong minima is a
characteristic of peptides existing in a random roil conformation.23 The Re(CO)3+
coordinated peptide resulted in two minima at 200 nm and 215 nm, and two maxima at
210 nm and 235 nm. Upon coordinating with a metal, a significant difference in the
peptide conformation was observed, suggesting that a turn was created in the peptide
backbone. The identification of the secondary structure remains unclear from just CD
data. To further explore the secondary structure of the coordinated peptide, variable
temperature (VT) NMR and computational studies were performed.
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Figure 3.4 Circular Dichroism (CD) analysis of linear peptide and Re(CO)3+ coordinated
peptide in H2O at 25 oC.

3.2.7
1

Variable Temperature (VT) NMR

H-NMR and CD spectroscopy demonstrated that a turn was established within the

peptide backbone. Secondary structure is a result of intra-molecular hydrogen bonding
within the peptide backbone that can be evaluated by studying the variable temperature
(VT) 1H-NMR of the compound.24,25 The formation of intra-molecular hydrogen bonds
results in the chemical shift of the amide proton being less affected by a change in
temperature when compared to non-hydrogen bonded or solvent-exposed amide
protons.26 This is due to the amide proton being held in a strong conformational lock by
the carbonyl oxygen. A non-hydrogen bonded amide proton shifts significantly up-field
as the temperature increases, whereas, a hydrogen bonded amide proton is less strongly
affected by temperature change. The hydrogen bonds can be classified as medium and
strong interactions. This can be demonstrated by deriving a numerical value (ΔδNH/ΔT),
chemical shift (ppm) divided by change in temperature (K). A temperature gradient of
ΔδNH/ΔT ≥ -3 ppbK-1, corresponds to strong intramolecular hydrogen bonding; and
ΔδNH/ΔT ≤ -4.5 ppbK-1 are suggestive of solvent-exposed protons, while intermediate
values between the two extremes suggest weak intra-molecular hydrogen bonding.27,28

54

Figure 3.5 VT NMR analysis of the rhenium coordinated peptide, 3.5, in DMSO-d6 at
600 MHz.
Amino acid residue (NαH)
3-Pridylalanine (&)
Aspartic Acid (#)
Glycine (*)
Arginine (@)

Δδ/ΔT (ppb/K)
- 3.1
- 3.4
- 3.1
- 2.6

H Bond
medium
medium
medium
strong

Table 3.3 Chemical shifts of amide protons expressed in numerical values, Δδ/ΔT
(ppb/K) for each amino acid residues.
VT NMR studies of the rhenium coordinated peptide, [Re(CO)3(pyta-RGD-3Pal-NH2)]+,
were carried out in DMSO-d6 from 25-60 oC. The seven 1H-NMR spectras for the amide
protons were obtained over the range of 35 oC, Figure 3.4. The amide protons are labelled
and changes in the chemical shifts of amide protons are observed. Table 3.3 reports
numerical values for changes in the chemical shifts of amide protons.
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When the chemical shifts were converted to numerical values, all the amide bonds were
present in the range of 0 ≥ Δδ/ΔT ≥ - 4.5 ppbK-1, indicating that hydrogen bonding exists
within the peptide backbone. This suggested that the amide protons within the peptide
backbone are involved in hydrogen bonding, either through backbone carbonyls of the
amide bonds or through side chain carbonyls, such as carboxylate functional group on the
aspartic acid. The arginine amide proton is considered to be strongly hydrogen bonded,
while other amide protons are only moderately hydrogen bonded. The moderate hydrogen
bonding could be the result of solvent exposure, as traces of water are present within the
sample, or weak intra-molecular hydrogen bonding.

3.2.8

Computational Study

To further explore the secondary structure of the peptide backbone, computational studies
on the coordinated peptide were performed. Two possible isomers were formed upon
metal coordination. All isomers were optimized using density functional theory (DFT),
employing B3LYP functional. One of the coordinated isomers, obtained in gas phase,
displayed consistent results observed with variable temperature (VT) NMR spectroscopy,
Figure 3.5. Multiple intra-molecular hydrogen bonds were observed in the peptide
backbone. According to the computational data, all the amide protons, expect the aspartic
acid amide proton, were hydrogen bonded, which is consistent with the results obtained
from variable temperature (VT) NMR studies. The aspartic acid amide proton was
hydrogen bonded according to the experimental results but this could be a result of
stabilization due to solvent exposure. The optimized structure suggest that the cyclized
peptide contains a i,i±3 turn.
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Figure 3.6 Lowest energy isomer of Re-coordinated peptide, 3.5, optimized using DFT
calculations, displaying intra-molecular hydrogen bonding.

3.2.9

99m

Tc Labelling

Scheme 3.4 99mTc(CO)3+ coordination of pyta-RGD-3Pal-NH2 to give 3.6.
The linear peptide, pyta-RGD-3Pal-NH2, was labelled with technetium-99m to provide
99m

Tc coordinated peptide, [99mTc(CO)3(pyta-RGD-3Pal-NH2)]. The pertechnetate was

added to the commercially available isolink kit, and following the microwave reaction
conditions reported by Pitchumony et al. resulted in [99mTc(CO)3(OH2)3]+.29 The reduced
99m

Tc was reacted with the linear peptide, producing the radiolabelled peptide. The crude

mixture was then purified a with Waters Sep-Pak C18 Plus Cartridge. To demonstrate
that the linear peptide was coordinated through 99mTc(CO)3+, the crude radiolabelled
peptide was co-injected with the purified Re(CO)3+ coordinated peptide, and confirmed
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by analytical U-HPLC. The retention time of the dominant isomer of the crude
radiolabelled peptide in the gamma trace correlated with the purified Re(CO)3+
coordinated peptide in the UV trace, Figure 3.6. From this result, it was concluded that
the 99mTc labeling of the linear peptide was successful.

Figure 3.7 U-HPLC analysis showing correlations between γ trace of crude 99mTc(CO)3+
labelled peptide and UV trance of purified Re(CO)3+ coordinated peptide.

3.2.10

Derivatives of [Re(CO)3(pyta-RGD-3-Pal-NH2)]+

The protein-peptide interactions highly depend on the structural geometry that the peptide
is present in. Changes in the structural geometry can reduce or enhance specific binding
affinity of a peptide. To further explore different structural geometry in the RGD
backbone, the L-amino acids were replaced with the D-amino acids. This resulted in
RGD backbone to adapt different structural geometry upon metal coordination. Figure
3.7 displays derivatives of [Re(CO)3(pyta-RGD-3-Pal-NH2)]OTf. The coordinated
peptides were characterized by LC-MS, 1H-, and gCOSY NMR spectroscopy.
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Figure 3.8 Derivatives of [Re(CO)3(pyta-RGD-3-Pal-NH2)]OTf.

3.3

Conclusion

A linear peptide, pyta-RGD-3Pal-NH2, was cyclized in a “2+1” fashion through a bidentate coordination from two nitrogen atoms on the pyridyl-triazole, and a mono-dentate
attack from the nitrogen atom on the pyridine. This was demonstrated by comparing 1HNMR spectra of linear and coordinated peptides. Circular Dichroism (CD) data suggested
formation of secondary structure upon metal coordination, and hydrogen bonding was
observed by variable temperature (VT) NMR spectroscopy studies. Intra-molecular
hydrogen bonding displayed by computational data were consistent with VT NMR
studies, however, they were not identical. Radiolabelling of the linear peptide with
99m

Tc(CO)3+, resulted in the same structural constraints presented by Re(CO)3+

coordination. We successfully demonstrated cyclization of a biological relevant peptide
stabilized through 99mTc/Re(CO)3+coordination.

3.4

Experimental

All the reagents and solvents were purchased from Sigma Aldrich, Chem-Impex, Nova
BioChem, and the Fmoc protected amino acids were purchased from Peptide
International and Apptec, and were used without further purification. Analytical HPLCMS was performed using a Waters Atlantis T3 C18 column 4.6 x 150 mm, 5 µm.
Preparative RP HPLC-MS was performed using a Waters Atlantis T3 Prep C18 OBD
column 19 x 150 mm, 5 µm. A gradient system was used consisting of: CH3CN + 0.1%
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v/v trifluoroacetic acid, TFA, (solvent A) and H2O + 0.1% v/v TFA (solvent B), and the
absorbance was detected using a Waters 2998 Photodiode Array Detector. Electrospray
Ionization (ESI) mass spectrum was obtained using a Micromass Quatro Micro LCT
mass spectrometer. For analytical U-HPLC-MS studies, a Waters, Inc. Acquity UPLC HClass system was used, combined with a Xevo QTof and a Bioscan Inc. FC-1000 FlowCount Radio-HPLC Detector System. For analytical UHPLC studies, a Waters Acquity
UPLC BEH C18 2.1 x 50 mm, 1.7 μm column was used. A gradient solvent system
consisting of CH3OH + 0.1% formic acid (solvent A) and H2O + 0.1% formic acid
(solvent B) was used. A Biotage Isolera One flash chromatography system was used for
flash column chromatography purification fitted with a Snap 12 g reversed phase C-18
column. Varian INOVA 600 NMR spectrometer was used for 1H, and gCOSY NMR
studies.

3.4.1

Small Molecule Synthesis

t-butyl azido acetate, 3.1
A modified procedure was used.14 tert-Butyl 2-bromoacetate (19.512g, 100 mmol) and
sodium azide (9.751 g, 150 mmol)were dissolved in 3:2 mixture of acetone (60 mL) and
water (40 mL). The solution was refluxed (92 oC) for 22 hours. Upon completion of the
reaction, the mixture was cooled to room temperature, and concentrated to remove
acetone. The organic product was extracted with Et2O (3x20 ml). The organic layers were
washed with sat. NaCl and dried over sodium sulfate, Na2SO4. The organic solution was
concentrated to give the product, 3.1 (11.5 g, 73 % yield), as a yellow oil. No additional
purification was performed prior to further reaction. 1H NMR (400 MHz, CDCl3, δ) 3.72
(s, 2H), 1.48 (s, 9H).
tert-butyl 2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetate, 3.2
A modified procedure was used.14 tert-Butyl azido acetate (0.489 g, 3.1 mmol) and 2ethynylpyridine (0.322 g, 3.1 mmol) were dissolved in isopropanol (1 mL) in a 20 mL
vial. In another 20 mL vial, copper (II) sulfate pentahydrate (0.041 g, 0.16 mmol) and Lascorbic acid (0.290 g, 1.6 mmol) were dissolved in H2O (2 mL). Solids were completely
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dissolved by sonicating for 20 minutes at room temperature. The aqueous solution was
added dropwise to the stirring organic solution over 15 minutes. The reaction mixture
was stirred at room temperature for 2 hours. The resulting solution was diluted with
chloroform (40 mL) and washed thrice with sat. disodium ethylenediaminetetraacetate
(3x20 mL).The organic product from the aqueous solution was extracted with chloroform
(3x20 mL). The organic layers were combined, dried over Na2SO4, and concentrated to
remove chloroform. The crude product was purified by Biotage Isolera One flash column
chromatography fitted with a normal phase cartridge, with methanol (Solvent A) in
dichloromethane (Solvent B) using 1–8% gradient to give 3.2 (0.60 g, 75 % yield) . 1H
NMR (400 MHz, CDCl3, δ) 8.58 (m, 1H), 8.25 (s, 1H), 8.18 (d, J = 7.9 Hz, 1H), 7.78 (td,
J = 7.8, 1.8 Hz, 1H), 7.23 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 5.12 (s, 2H), 1.49 (s, 9H).
2-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)acetic acid (pyta) 3.3
In a 20 mL microwave vial, pyridyl-triazole acetate (0.60 g, 0.23 mmol) was dissolved in
methanol (18 mL). The solution was heated under microwave conditions for 2.5 hours at
130 oC. The reaction mixture was cooled to room temperature, and precipitates were
observed. The reaction mixture was vacuum filtered to give 3.3 (0.12 g, 25 % yield). No
further purification was needed. 1H NMR (400 MHz, D2O, δ) 8.84 (s, 1H), 8.72 (d, J =
5.4 Hz, 1H), 8.60 (t, J = 7.9 Hz, 1H), 8.37 (d, J = 8.0 Hz, 1H), 7.97 (t, J = 6.1 Hz, 1H),
5.42 (s, 2H).

3.4.2

Peptide Synthesis

Pyta-RGD-3-Pal-NH2, 3.4
The Peptide was synthesized from C⟶N terminus using standard Fmoc Solid Phase
Synthesis (Fmoc-SPPS) approach. Synthesis was carried out manually at room
temperature. Fmoc protected Rink amide (0.54 mmol/g) resin was used as solid support.
The resin was swollen in dichloromethane (DCM) for 15 minutes. The Fmoc group was
removed using 20% piperidine in N,N-dimethylformamide (DMF) over two cycles (5 and
15 minutes). Coupling reactions were carried out with 3 eq. Fmoc protected amino acid, 3
eq. HCTU (2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-
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tetramethylaminiumhexafluorophosphate) and 6 eq. of DIPEA (N,Ndiisopropylethylamine). Each cycle was vortexed for 60-90 minutes. The resin was
washed with excess DMF and DCM after each coupling and de-protection cycles.
Pyridyl-triazole, pyta, was vortexed in DMF at room temperature, with 9 eq. of DIPEA
and 3 eq. of TSTU (O-(N-succinimidyl)-1,1,3,3-tetramethyl uranium tetrafluoroborate),
for an hour before adding to the resin for coupling reaction. After constructing the desired
peptide sequence, the peptide was cleaved off the resin with 95% (v/v) trifluroacetic acid
(TFA), 2.5% (v/v) triisopropylsilane (TIPS) and 2.5% (v/v) H2O. The cleavage was
performed for 4 hours. The cleaved peptide was precipitated with tert-butyl methyl ether
(TBME), and centrifuged at 4000 rpm for 10 minutes. After decanting, the peptide was
frozen and lyophilized to remove any remaining solvents. The peptide was purified with
reverse phase preparative LC-MS, and the purity was checked by analytical HPLC. The
peptide resulted with a purity of > 95%. HRMS: m/z calculated for C32H37N13O10,
680.2979; observed [M]+ 680.2443 1H-NMR Spectrum (600 MHz, (CD3)2SO, δ): 10.07
(s, 1H), 8.86 (t, J = 5.5 Hz, 1H), 8.72 (t, J = 7.3 Hz, 2H), 8.60 (ddd, J = 4.8, 1.7, 1.0 Hz,
1H), 8.51 (s, 1H), 8.41 (d, J = 2.0 Hz, 1H), 8.38 (dd, J = 4.8, 1.6 Hz, 1H), 8.03 (m, 1H),
7.89 (m, 1H), 7.61 – 7.55 (m, 2H), 7.36 – 7.32 (m, 2H), 7.25 (dd, J = 7.7, 4.8 Hz, 1H),
7.19 (s, 1H), 7.02 (s, 2H), 5.26 (s, 2H), 4.41 – 4.32 (m, 3H), 4.28 – 4.22 (m, 1H), 3.98
(dd, J = 16.9, 6.7 Hz, 1H), 3.49 (dd, J = 16.8, 4.8 Hz, 1H), 3.22 – 3.15 (m, 1H), 3.12 (dd,
J = 14.3, 4.5 Hz, 1H), 2.98 (dd, J = 12.8, 8.3 Hz, 1H), 2.90 (dd, J = 14.2, 9.1 Hz, 1H),
2.57 – 2.51 (m, 1H), 2.22 (dd, J = 15.9, 4.9 Hz, 1H), 2.02 (s, 1H), 1.64 (dd, J = 11.9, 7.3
Hz, 1H), 1.50 (dd, J = 18.1, 7.9 Hz, 2H).
Pyta-RGd-3-Pal-NH2, 3.7
The peptide was synthesized manually on a Rink Amide resin using general SPPS. ESILC-MS: m/z calculated for C33H37N13O10 680.298 and [M+2H]2+ 340.653; observed
[M+H]+ 680.338 and [M+2H]2+ 340.717. 1H NMR (600 MHz, (CD3)2SO, δ) 8.78 (d, J =
7.4 Hz, 1H), 8.75 – 8.71 (m, 1H), 8.61 (m, 1H), 8.52 (s, 1H), 8.43 (d, J = 2.0 Hz, 1H),
8.39 (dd, J = 4.8, 1.6 Hz, 1H), 8.18 (d, J = 6.9 Hz, 1H), 8.03 (d, J = 7.9 Hz, 1H), 7.90 (td,
J = 7.7, 1.8 Hz, 1H), 7.82 (d, J = 8.8 Hz, 1H), 7.63 (dt, J = 7.8, 1.8 Hz, 1H), 7.41 (s, 1H),
7.35 (ddd, J = 7.5, 4.8, 1.1 Hz, 1H), 7.28 (s, 1H), 7.25 (dd, J = 7.7, 4.8 Hz, 1H), 7.00 (s,
2H), 5.31 – 5.22 (m, 2H), 4.32 – 4.27 (m, 2H), 4.10 (d, J = 5.3 Hz, 1H), 3.89 (dd, J =
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17.0, 7.3 Hz, 1H), 3.57 (dd, J = 17.0, 4.2 Hz, 1H), 3.27 (dd, J = 13.9, 3.4 Hz, 1H), 3.18
(dd, J = 12.3, 5.7 Hz, 1H), 3.14 – 3.07 (m, 1H), 2.79 (dd, J = 14.0, 11.1 Hz, 1H), 2.49 –
2.44 (m, 1H), 2.05 – 1.99 (m, 1H), 1.99 – 1.92 (m, 1H), 1.72 (dd, J = 16.5, 7.8 Hz, 1H),
1.66 – 1.51 (m, 2H).
Pyta-rGD-3-Pal-NH2, 3.8
The peptide was synthesized manually on a Rink Amide resin using general SPPS. ESILC-MS: m/z calculated for C33H37N13O10 680.298 and [M+2H]2+ 340.653; observed
[M+H]+ 680.270 and [M+2H]2+ 340.717. 1H NMR (599 MHz, dmso) δ 8.74 (d, J = 7.7
Hz, 1H), 8.71 (dd, J = 11.1, 5.2 Hz, 1H), 8.63 (d, J = 6.6 Hz, 1H), 8.60 (ddd, J = 4.9, 1.6,
0.8 Hz, 1H), 8.51 (s, 1H), 8.41 (d, J = 1.9 Hz, 1H), 8.38 (dd, J = 4.8, 1.6 Hz, 1H), 8.03 (d,
J = 7.9 Hz, 1H), 7.89 (td, J = 7.7, 1.8 Hz, 1H), 7.70 (d, J = 8.2 Hz, 1H), 7.61 (dt, J = 7.8,
1.8 Hz, 1H), 7.38 (s, 1H), 7.34 (ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 7.24 (dd, J = 7.7, 4.8 Hz,
1H), 7.15 (s, 1H), 7.02 (s, 2H), 5.24 (d, J = 1.9 Hz, 2H), 4.35 (ddd, J = 15.1, 9.6, 6.4 Hz,
2H), 4.23 (d, J = 6.0 Hz, 1H), 3.93 (dd, J = 16.9, 7.3 Hz, 1H), 3.52 (dd, J = 16.9, 4.3 Hz,
1H), 3.10 (dd, J = 13.7, 4.4 Hz, 3H), 2.90 (dd, J = 10.5, 5.6 Hz, 1H)., 2.46 (dd, J = 15.7,
5.3 Hz, 1H), 2.15 (d, J = 16.1 Hz, 1H), 1.95 (dd, J = 14.1, 9.2 Hz, 1H), 1.65 (ddd, J =
18.4, 11.6, 4.8 Hz, 1H), 1.61 – 1.48 (m, 2H).

3.4.3

Metal Coordination

[Re(CO)3(pyta-RGD-3-Pal-NH2]OTf, 3.5
The purified linear peptide, 3.4, (30.9 mg, 0.046 mmol) was coordinated
[Re(CO)3(OH2)3]OTf (451 µL of 0.1 M solution, 0.045 mmol) in water (4 mL). The
reaction was performed under microwave conditions at 130 oC for an hour. Upon
completion of reaction, the crude mixture was lyophilized and purified by preparative
HPLC (linear gradient of 22 – 35 % Solvent A in B). The purity of the coordinated
peptide was determined by analytical LC-MS with ~ 90 % purity (linear gradient 23 – 75
% Solvent A in B). HRMS: m/z calculated for C33H37N13O10185/187Re, 948.23/950.23;
observed [M]+948.2238/950.2157. 1H NMR (600 MHz, (CD3)2SO, δ) 12.36 (s, 1H), 9.32
(d, J = 5.5 Hz, 1H), 9.31 (d, J = 5.0 Hz, 1H), 9.00 (s, 1H), 8.48 (t, J = 5.8 Hz, 1H), 8.41
(d, J = 5.4 Hz, 1H), 8.28 (td, J = 7.9, 1.4 Hz, 1H), 8.15 (d, J = 7.9 Hz, 1H), 7.91 (d, J =
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8.2 Hz, 1H), 7.87 (s, 1H), 7.80 (m, 1H), 7.59 (t, J = 5.9 Hz, 1H), 7.41 (dd, J = 7.9, 5.7
Hz, 1H), 7.37 (s, 1H), 7.35 (d, J = 4.6 Hz, 1H), 7.30 (s, 1H), 7.16 (d, J = 8.1 Hz, 1H),
5.78 (d, J = 16.7 Hz, 1H), 5.62 (d, J = 16.7 Hz, 1H), 4.42 (ddd, J = 12.5, 9.7, 3.2 Hz, 1H),
4.29 (dd, J = 14.9, 8.1 Hz, 1H), 4.18 (dd, J = 12.5, 6.7 Hz, 1H), 3.81 (dd, J = 16.2, 6.7
Hz, 1H), 3.52 (dd, J = 16.1, 4.8 Hz, 1H), 3.18 (td, J = 13.8, 6.9 Hz, 2H), 3.12 (d, J = 11.7
Hz, 1H), 1.82 – 1.74 (m, 1H), 1.69 (d, J = 10.3 Hz, 1H), 1.66 – 1.59 (m, 2H), 1.58 – 1.50
(m, 1H).
[99mTc(CO)3(pyta-RGD-3-Pal-NH2)] +, 3.6
[99mTcO4]- (1.0 mL, 337 MBq) was added to a previously prepared isolink kit containing
8.5 mg sodium tartrate, 2.85 mg Na2B4O7.10H2O, 7.15 mg sodium carbonate and 4.5 mg
sodium boranocarbonate. To a microwave vessel, 99mTc solution (1 mL) was added with
100 µL of 1 M HCl solution, and the reaction was performed for 3.5 minutes at 110 oC to
give [99mTc(CO)3(OH2)3]+. 46.7 MBq of [99mTc(CO)3(OH2)3]+ was added to a separate
microwave vessel containing the purified linear peptide (0.5 mg, 0.74 µmol) in water (1
mL). The labelled peptide was purified with Waters Sep-Pak Plus C18 Cartridge using 25
% acetonitrile in water, to remove unreacted linear peptide. The labelled peptide was
mixed with purified Re(CO)3+ coordinated peptide, and the solution was analyzed by
analytical Ultra HPLC (UHPLC).

[Re(CO)3(pyta-RGd-3-Pal-NH2]OTf, 3.9
The reaction was proceeded similar to 3.5, using the linear peptide 3.7. ESI-LC-MS: m/z
calculated for C33H37N13O10185/187Re, 948.23/950.23; observed [M]+ 948.441/950.557. 1H
NMR (600 MHz, (CD3)2SO, δ) 9.27 (s, 2H), 9.12 (s, 1H), 8.37 (d, J = 5.4 Hz, 1H), 8.25
(t, J = 7.7 Hz, 1H), 8.08 (d, J = 7.9 Hz, 1H), 8.05 (s, 1H), 7.85 (d, J = 7.8 Hz, 1H), 7.79
(s, 1H), 7.76 (t, 1H), 7.74 (s, 1H), 7.63 (t, 1H), 7.33 – 7.27 (m, 3H), 7.24 (s, 1H), 7.09 (s,
1H), 5.75 (d, J = 15.8 Hz, 1H), 5.46 (d, J = 15.8 Hz, 1H), 4.07 (dd, J = 13.5, 6.2 Hz, 1H),
4.00 (dd, J = 9.3, 8.3 Hz, 1H), 3.76 (dd, J = 15.8, 6.3 Hz, 1H), 3.72 – 3.66 (m, 2H), 3.52
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(dd, J = 15.7, 4.8 Hz, 3H), 3.15 (d, J = 7.1 Hz, 2H), 2.46 – 2.38 (m, 3H), 2.32 (dd, J =
16.8, 8.0 Hz, 1H), 1.83 – 1.74 (m, J = 13.7 Hz, 1H), 1.71 – 1.51 (m, 4H).

[Re(CO)3(pyta-rGD-3-Pal-NH2]OTf, 3.10
The reaction was proceeded similar to 3.5, using the linear peptide 3.8.ESI-LC-MS: m/z
calculated for C33H37N13O10185/187Re, 948.23/950.23; observed [M]+ 948.2433/950.2352.
1

H NMR (600 MHz, (CD3)2SO, δ) 12.32 (s, 1H), 9.29 (d, J = 5.4 Hz, 1H), 9.22 (d, J = 4.4

Hz, 1H), 9.16 (s, 1H), 8.64 (m, 1H), 8.28 (t, J = 7.8 Hz, 1H), 8.23 (t, J = 7.1 Hz, 2H), 8.08
(s, 1H), 7.80 (t, J = 6.6 Hz, 1H), 7.57 – 7.53 (m, 2H), 7.46 (d, J = 6.6 Hz, 1H), 7.41 (m,
1H), 7.35 (d, J = 9.1 Hz, 1H), 7.25 (s, 1H), 7.11 (s, 1H), 6.52 (s, 2H), 5.66 (d, J = 15.6
Hz, 1H), 5.39 (d, J = 15.7 Hz, 1H), 4.18 (q, J = 7.1 Hz, 1H), 4.02 – 3.93 (m, 2H), 3.89
(dd, J = 16.6, 7.1 Hz, 1H), 3.55 (dd, J = 16.5, 3.9 Hz, 1H), 3.18 – 3.07 (m, 3H), 2.38 (dd,
J = 16.8, 7.4 Hz, 1H), 2.22 (dd, J = 16.6, 6.4 Hz, 1H), 2.08 (d, J = 7.4 Hz, 1H), 1.76 –
1.70 (m, 1H), 1.69 – 1.64 (m, J = 5.5 Hz, 1H), 1.62 – 1.57 (m, 1H), 1.56 – 1.51 (m, 1H).

3.4.4

Circular Dichroism (CD) spectroscopy

The samples were dissolved in water, and diluted till absorbance reached a value of 1.
The absorbance was measured by UV VIS spectrometer. The spectra were collected at 20
o

C with scan rate of 100 nm min-1, averaged over ten accumulations. The path length of

the cuvette was 0.1 mm. Data were converted to mean residue ellipticity units, and
plotted in Graphpad prism.

3.4.5

Computational Studies

All the structures were initially constructed by DS viewer 3.5. The optimization of
structures was performed using density functional theory (DFT), employing the B3LYP
functional. The LANL2DZ pseudopotential and the 6-31G(d) basis set were used to
model rhenium and the remaining atoms, respectively. No geometry restraint was applied
during all optimizations. The nature of the optimized structures and energy minima were
defined by subsequent frequency calculations. All calculated structures were
characterized as true minima. All the calculations were performed with Gaussian 09
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(RevD.01)30 on high-performance computing (HPC) facilities within the Compute
Canada network.31
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Chapter 4

4

Conclusion

Molecular imaging is a well-established in-vivo characterization and visualization
technique that provides an insight into the biological events taking place at the molecular
and cellular level.1,2 This technique avoids biopsy, and enables non-invasive
identification of disease on-set and progression. Three major components are associated
when designing a molecular imaging probe: a) a biological target, b) a targeting entity,
and c) a signalling source. Many advances have been made in designing imaging probes
for PET and SPECT imaging, for both clinical and research applications. The current
generation of radiopharmaceuticals are expensive, lack specificity for targeted receptors,
are rapidly excreted from the body, and also lack a repetitive method for synthesizing
radiopharmaceuticals. Therefore, the development of new techniques for the design of
radiopharmaceuticals that allows for both quick and efficient ways to introduce radionuclides, as well as to improve in-vivo stability and binding affinity, is an attractive topic
of research.
Protein-protein interactions are essential for many biological processes, making them an
attractive target for drug discovery and therapeutics.3,4 Intergrins are type I
transmembrane proteins that mediate protein-protein interactions, and regulate cell shape,
cell cycle, and cell migration.5,6 Integrins, in particular αvβ3, are overexpressed at tumor
cells, while present at low concentration in normal tissue cells. Preventing protein-protein
interactions can serve as a potential therapeutic for tumor suppression. Eight of 24
integrins, including αvβ3, share an identical recognition site, a tripeptide sequence (RGD),
for their protein-protein interactions. Cyclic RGD peptides have been shown to exhibit
better binding affinity towards αvβ3, when compared to their linear counterparts.
Introducing structural constraints, through metal-based cyclization, within a peptide
backbone, has shown to improve in-vivo stability and binding affinity of the original
peptide.
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In this thesis, the development of cyclic RGD peptides, stabilized through
99m

Tc/Re(CO)3+ coordination, was explored. Mono- and bi-dentate ligands were used at

the end terminals of a linear peptide. Cyclization of the linear peptide was demonstrated
such that the terminal ligands were able to coordinate with 99mTc/Re(CO)3+ in a “2+1”
fashion, resulting in a cyclic peptide that represented an integrated design. This is an
innovative approach of introducing structural constraints through metal based cyclization,
and in doing so triggering biological activity of a peptide.
99m

Tc/Re (I) coordination can be achieved by employing natural and un-natural amino

acids. Histidine can act as mono-, bi-, and tri-dentate ligand, effectively stabilizing a turn
upon metal coordination.7,8 Simpson demonstrated cyclization of Ac-HAAAH-OH
through 99mTc/Re(CO)3+ coordination.8 A “2+1” chelation system was created, with a bidentate attack at the C-terminus and mono-dentate coordination at the N-terminus.
Coordination of Ac-HRGDH-OH with [Re(CO)3(OH2)3]OTf gave numerous isomers that
were present in close proximity by chromatography, and isolating a single isomer for
further characterization was challenging. To reduce the number of isomers, un-natural
amino acids such as 2-pyridylalanine, 3-pyridylalanine, and 4-pyridylalanine were used
as a replacement for histidine residues. The coordination of the linear peptide, employing
pyridylalanine amino acids, with Re(CO)3+ resulted in fewer number of isomers; and a
single isomer for [Re(CO)3(Ac-3-Pal-RGD-3-Pal-OH)]OTf was isolated. However, the
stability of the isolated isomer presented an issue, as it was converted to various isomeric
forms.
Employing amino acids as bi-dentate chelators did not provide satisfying results for
further characterization. The strong metal chelator, pyridyl-triazole (pyta), was used as a
bi-dentate chelator at the N-terminus instead of using an amino acid. A linear peptide,
pyta-RGD-3Pal-NH2, was synthesized and cyclized in a “2+1” chelation fashion. The
linear and coordinated peptides were characterized by 1H- and 2D-NMR spectroscopy. A
turn was created upon metal coordination that was demonstrated by comparing circular
dichroism (CD) data of linear and coordinated peptides. Intra-molecular hydrogen
bonding was observed by variable temperature (VT) NMR studies. The data obtained
from a computational study, where the coordinated peptide was optimized using DFT
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calculations, were consistent, but not identical, with VT NMR studies. The linear peptide
was radiolabeled with 99mTc(CO)3+, and resulted in the same dominant isomer presented
by Re(CO)3+ coordination.
In conclusion, we successfully demonstrated cyclization of RGD peptides that were
stabilized through 99mTc/Re(CO)3+ coordination and resulted in a “2+1” chelation. To
further investigate the cyclic RGD backbone, L-amino acids were replaced with D-amino
acids; this resulted in different structural geometry within the peptide backbone. These
cyclic rhenium coordinated peptides, will first be tested for their binding affinity towards
integrins αvβ3, by performing competitive in-vitro assays, such as enzyme-linked
immunosorbent assay (ELISA). The differences in the structural geometry of these
cyclized peptides will be compared by computational studies. Finally, in-vivo studies on
the cyclic peptide with the best in-vitro results will be evaluated against human
melanoma cell line A375M, which expresses integrin αvβ3. The 99mTc(CO)3+ labeled
peptide has a potential to be used for imaging of angiogenesis associated with cancer.
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Appendices
Appendix A: Chromatograms of selected compounds
Ac-HRGDH-OH, 2.4

Ac-HRGDH-NH2
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Ac-3-Pal-RGD-3-Pal-OH, 2.7

Ac-3-Pal-RGD-3-Pal-NH2, 2.8

75

[Re(CO)3(Ac-HRGDH-NH2)(py)]+

pyta-RGD-3-Pal-NH2, 3.4
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pyta-RGd-3-Pal-NH2, 3.7

pyta-rGD-3-Pal-NH2, 3.8

77

[Re(CO)3(pyta-RGD-3-Pal-NH2)]OTf, 3.5

[Re(CO)3(pyta-RGd-3-Pal-NH2)]OTf, 3.9
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[Re(CO)3(pyta-rGD-3-Pal-NH2)]OTf, 3.10
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Appendix B: 1H- and COSY NMR spectra of linear and
Re(CO)3+ coordinated peptides
Ac-HRGDH-OH, 2.4
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tert-butyl azido acetate, 3.1

81

tert-butyl 2-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)acetate, 3.2

82

2-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)acetic acid (pyta), 3.3

83

pyta-RGD-3-Pal-NH2, 3.4

84

85

pyta-RGd-3-Pal-NH2, 3.7

86

87

pyta-rGD-3-Pal-NH2, 3.8

88

89

[Re(CO)3(pyta-RGD-3-Pal-NH2)]OTf, 3.5

90

91

[Re(CO)3(pyta-RGd-3-Pal-NH2)]OTf, 3.9

92

93

[Re(CO)3(pyta-rGD-3-Pal-NH2)]OTf, 3.10

94
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Appendix C: Computational study on Re(CO)3+ coordinated
peptide, 3.5
3D structures, showing intra-molecular hydrogen bonding (dashed red lines), of two
possible isomers for the proposed structure of cyclized peptide, 3.5
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